🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆ Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Ulm
Clinical trial register · Germany

Clinical Trials in Ulm, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Germany and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 5051 matching records held by the registry are in this view. Synced 26 Sep 2026, 19:51 UTC
5051
Studies in scope
all four open statuses
2882
Recruiting now
open to new participants
988
Lead sponsors
across recruiting studies
Top sites
Berlin 1584 Hamburg 889 Essen 760 Dresden 707 Heidelberg 627
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
University of Ulm24 Hoffmann-La Roche23 AbbVie21 Novartis Pharmaceuticals14 Eli Lilly and Company13
Site location
Berlin1584 Hamburg889 Essen760 Dresden707 Heidelberg627
All 635 locations
Target enrolment
to

Trials with a site in Ulm

348 of 5051 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Germany
Start
Not yet open
Minimally-invasive ICG-guided Retroperitoneal Sentinel Lymph Node Dissection in the Primary Staging of Testicular Cancer Versus Standard of Care
NCT07699640Testicular Cancer, Testicular Germ Cell Tumor
Heinrich-Heine University, Duesseldorf
Not applicable
171
Ulm, Würzburg, Hamburg, Marburg, Cologne, Düsseldorf, Wuppertal, Dresden
2027-01
Not yet open
A Study to Evaluate Adverse Events and Change in Disease Activity With Injected Etentamig Plus Oral Pomalidomide Versus Standard Therapies in Adults With Relapsed or Refractory Multiple Myeloma
NCT07728188Relapsed or Refractory Multiple Myeloma
DrugsEtentamig·Teclistamab·Carfilzomib·Pomalidomide
AbbVie
Phase 3
520
Freiburg im Breisgau, Karlsruhe, Tübingen, Ulm, Würzburg, Hanover, Bonn, Cologne
2026-11-30
Not yet open
Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02)
NCT07680790Non-Small Cell Lung Cancer
DrugsIza-bren·Osimertinib·Pemetrexed·Cisplatin
Bristol-Myers Squibb
Phase 3
850
Gerlingen, Ulm, Wangen, Munich, Regensburg, Frankfurt am Main, Oldenburg, Cologne
2026-09-30
Recruiting
A Study to Evaluate the Efficacy of VVD-133214 in Combination With Pembrolizumab Compared With Pembrolizumab Alone in Participants With Advanced Cancer of the Colon or Rectum
NCT07811193Colorectal Adenocarcinoma
DrugsVVD-133214·Pembrolizumab
Vividion Therapeutics, Inc.
Phase 2
140
Ulm, Schweinfurt, Hamburg, Frankfurt am Main, Oldenburg, Essen, Berlin
2026-09-11
Not yet open
Paclitaxel, Ramucirumab and Tislelizumab Switch Maintenance in Advanced HER2-negative and PD-L1 TAP Score of 5 or More Advanced Gastroesophageal Adenocarcinoma
NCT07763171Gastroesophageal Adenocarcinoma
DrugsRamucirumab·Folfox·Tislelizumab·Paclitaxel
Gruppo Oncologico del Nord-Ovest
Phase 3
244
Frankfurt, Hamburg, München, Ulm
2026-09-01
Recruiting
Open-label Gene Therapy Study in p47-CGD
NCT07826767Chronic Granulomatous Disease (CGD)
Somagenetix AG
Phase 1/2
5
Ulm
2026-08-18
Recruiting
Pridopidine Phase 3 Study in Huntington's Disease
NCT07609108Huntington Disease
DrugPridopidine
Prilenia
Phase 3
400
Aachen, Bochum, Erlangen, Münster, Taufkirchen, Ulm
2026-07-01
Recruiting
A Trial to Compare Treatment With Surlorian (ARM210, S48168) to Placebo in Effects on Muscle Strength and Safety in Adults With Autosomal Dominant RYR1-related Myopathy
NCT07560020Autosomal Dominant RYR1-Related Myopathy
RyCarma Therapeutics, Inc.
Phase 2
28
Ulm, Berlin
2026-07-01
Not yet open
ORAL-PROTECT I: Oral Asepsis Preventing Transmission During Intubation
NCT07669064Bacterial Transmission, Intubation Intratracheal, Chlorhexidine
University Hospital Ulm
Not applicable
60
Ulm
2026-06-20
Recruiting
ToPanc Trial: Survival After Total Versus Partial Pancreaticoduodenectomy for Adenocarcinoma of the Pancreatic Head, Distal Cholangiocarcinoma, and Ampullary Cancer
NCT06801899Pancreatic Cancer
Insel Gruppe AG, University Hospital Bern
Not applicable
170
Münster, Ulm
2026-06-01
Recruiting
A Substudy of LY4256984 in Participants With Sporadic Amyotrophic Lateral Sclerosis
NCT07571174Amyotrophic Lateral Sclerosis
DrugLY4256984
Eli Lilly and Company
Phase 1
32
Lübeck, Rostock, Ulm
2026-05-14
Recruiting
A Master Protocol (OLMP): A Study of LY4256984 in Participants With Amyotrophic Lateral Sclerosis (ALS)
NCT07571200Amyotrophic Lateral Sclerosis
DrugLY4256984
Eli Lilly and Company
Phase 1
32
Lübeck, Rostock, Ulm
2026-05-14
Recruiting
Safety and Clinical Applicability of Transcorneal Electrical Stimulation (TES) in Geographic Atrophy
NCT07531927Geographic Atrophy Secondary to Age-related Macular Degeneration
Okuvision GmbH
Not applicable
70
Hamburg, München, Stuttgart, Tübingen, Ulm
2026-05-05
Recruiting
Glucose-Level During Endurance Exercise
NCT07543705Glucose Metabolism
University of Ulm
Observational
100
Ulm
2026-05-05
Recruiting
A Study of LY4395089 and Mirikizumab (LY3074828) Given Together and Mirikizumab (Alone) in Adults With Crohn's Disease
NCT07483099Crohn Disease
DrugsLY4395089·Mirikizumab
Eli Lilly and Company
Phase 2
60
Berlin, Dachau, Halle, Ludwigshafen, Ulm
2026-05-04
Recruiting
A Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn's Disease
NCT07483073Colitis, Ulcerative, Crohn Disease
DrugsLY4395089·Mirikizumab
Eli Lilly and Company
Phase 2
60
Berlin, Dachau, Halle, Ludwigshafen, Ulm
2026-05-04
Recruiting
A Prospective Observational Trial to Assess Treatment Sequences and Factors That Impact Overall Sur-vival in Patients With Chronic Lymphocytic Leukaemia (CLL) Treated Within First-line Studies of the GCLLSG
NCT06792994Chronic Lymphocytic Leukemia
German CLL Study Group
Observational
2,000
Cologne, Ulm
2026-04-02
Not yet open
The Importance of Insulin Action in the Brain for the Immune System During Physical Activity-Overweight
NCT07466173Insulin Sensitivity
University of Ulm
Not applicable
8
Ulm
2026-04
Recruiting
Imprinting in Metabolic Diseases - Identifying Epigenetic Mechanisms in Human Gestational Diabetes Through Cell-free DNA
NCT07436195Gestational Diabetes Mellitus (GDM)
University of Ulm
Observational
80
Ulm
2026-03-30
Recruiting
Cerebral Small Vessel Disease Progression Dependent on Stroke Type
NCT07611136Cerebral Small Vessel Disease, Stroke, Stroke Recurrence, Biomarkers
Johannes Dorst
Observational
180
Ulm
2026-03-26
Recruiting
A Study to Evaluate Efficacy and Safety of MK-8690 in Participants With Moderately to Severely Active Ulcerative Colitis (MK-8690-002)
NCT07463183Colitis Ulcerative, Ulcerative Colitis
Merck Sharp & Dohme LLC
Phase 2
100
Ulm
2026-03-24
Recruiting
A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease
NCT07326709Huntington Disease
DrugVotoplam
Novartis Pharmaceuticals
Phase 3
770
Aachen, Bochum, Münster, Tübingen, Ulm
2026-03-24
Not yet open
The EMBRACE Registry: European Post-Market Registry for Catheter Based Mitral Valve Replacement
NCT07409285Mitral Regurgitation
HighLife SAS
Observational
150
Ulm
2026-03-14
Recruiting
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)
NCT07221149Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
DrugsPumitamig·Folfox·Nivolumab
Bristol-Myers Squibb
Phase 2/3
690
Berlin, Frankfurt, Hamburg, Heidelberg, Leipzig, Mainz, Mannheim, Ulm
2026-03-13
Recruiting
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis (MS)
NCT07282574Progressive Multiple Sclerosis
DrugOcrelizumab
Hoffmann-La Roche
Phase 2
360
Freiburg im Breisgau, Mannheim, Tübingen, Ulm, Erlangen, Munich, Bochum, Düsseldorf
2026-03-10
Not yet open
Study on Risk Assessment for Patients With Microscopic Hematuria (Non-Visible Blood in Urine) Using a Urine Marker Test
NCT07307300Hematuria
Christian Bolenz
Observational
1,475
Ulm
2026-03
Recruiting
A Study to Learn More About the Change in the Blood Levels of Transthyretin When Participants With Transthyretin Amyloidosis With Cardiomyopathy Switch From Tafamidis to Acoramidis
NCT07298044Transthyretin Amyloid Cardiomyopathy
DrugAcoramidis
Bayer
Phase 4
50
Ulm, Darmstadt, Greifswald, Bonn, Berlin, Hamburg
2026-02-13
Recruiting
A Study Evaluating Mibavademab Treatment of Obesity Due to Leptin (LEP) Gene Mutations in Children, Adolescents and Adults
NCT07220772Monogenic Obesity
DrugMibavademab
Regeneron Pharmaceuticals
Phase 3
4
Ulm
2026-02-09
Recruiting
A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE)
NCT07222332Diabetes Mellitus, Type 1
DrugBaricitinib
Eli Lilly and Company
Phase 3
300
Hanover, Hof, Karlsburg, Ludwigshafen am Rhein, München, Oldenburg, Sankt Augustin, Ulm
2026-02-05
Recruiting
Impact of Thyroid Hormones on Human Glucose and Energy Metabolism
NCT07410637Graves Disease, Thyroid Cancer
University of Ulm
Not applicable
60
Ulm
2026-02-04
Recruiting
Pridopidine Phase 3 Study to Evaluate Efficacy and Safety in ALS
NCT07322003Amyotrophic Lateral Sclerosis
DrugPridopidine
Prilenia
Phase 3
500
Berlin, Bonn, Jena, München, Ulm
2026-02-01
By invitation
Long-Term Follow-Up of AvenCell Sponsored CAR-T Cell Clinical Trials
NCT07474051B-cell Lymphoma, Chronic Lymphocytic Leukemia, Hematologic Malignancy, AML (Acute Myelogenous Leukemia)
DrugAllo-QuadCAR01-T
AvenCell Therapeutics, Inc.
Observational
178
Berlin, Dresden, Marburg, Munich, Ulm
2026-01-29
Recruiting
Neoadjuvant Darovasertib in Primary Uveal Melanoma
NCT07015190Uveal Melanoma
DrugDarovasertib
IDEAYA Biosciences
Phase 3
520
Tübingen, Ulm, Erlangen, Essen, Dessau, Berlin, Bonn, Lübeck
2026-01-25
Recruiting
A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
NCT07184944Crohn's Disease
DrugDuvakitug
Sanofi
Phase 3
751
Ulm
2026-01-22
Recruiting
A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis
NCT07185009Ulcerative Colitis
DrugDuvakitug
Sanofi
Phase 3
751
Ulm
2026-01-16
Recruiting
Functional Impact of Acute Respiratory Viral Infections in Older Adults
NCT07388173Respiratory Infections in Old Age
University Hospital, Grenoble
Observational
1,600
Bayreuth, Göttingen, Jena, Mannheim, Ulm
2026-01-15
Recruiting
Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression
NCT07155226Acute Lymphoblastic Leukaemia, Acute Myeloid Leukaemia, Higher-risk Myelodysplastic Syndromes
DrugPosaconazole
AstraZeneca
Phase 1/2
84
Dresden, Frankfurt A. Main, Halle, Heidelberg, München, Ulm
2026-01-09
Recruiting
Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies
NCT07284433Lymphoma Diffuse Large B-cell, Leukemia and Lymphoma, Leukemia Relapse, Lymphoma Receiving CAR-T Therapy
DrugAllo-QuadCAR01-T
AvenCell Therapeutics, Inc.
Phase 1/2
178
Ulm, Erlangen, Munich, Marburg, Essen, Dresden, Berlin, Hamburg
2026-01-06
Recruiting
A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
NCT07063745Metastatic Non-small Cell Lung Cancer With MTAP Deletion
DrugsNavlimetostat·Nab-paclitaxel·Pemetrexed·Paclitaxel
Bristol-Myers Squibb
Phase 2/3
590
Göppingen, Stuttgart, Tübingen, Ulm, Donauwörth, München, Regensburg, Traunstein
2026-01-02
Recruiting
Disentangling the Effect of Brain Insulin Resistance on Brain Health
NCT07374705Diabetes Type 2, Diabetes Type 1
Henrik Bo Wiberg Larsson
Observational
150
Ulm
2026-01-01
Recruiting
Pathogen-Reduced Platelet Concentrates: Experience in Routine Practice in Germany
NCT07354672Platelet Transfusion
Deutsches Rotes Kreuz DRK-Blutspendedienst Baden-Wurttemberg-Hessen
Observational
850
Ulm
2025-12-22
Recruiting
Development of the PTSD-iMPACT to Measure PTSD-Related Functional Impairment in Children and Adolescents - A Validation Study in Switzerland and Germany
NCT07368166PTSD - Post Traumatic Stress Disorder, PTSD-Related Functional Impairment in Children and Adolescents
University Children's Hospital, Zurich
Observational
1,200
Aachen, Bamberg, Eichstätt, Konstanz, Marburg, Oldenburg, Ulm
2025-12-15
Recruiting
Efficacy of Semaglutide s.c. Once-weekly on Weight Loss and Management in Adolescents With Monogenic Obesity in Clinical Practice
NCT07302802Monogenic Obesity
DrugSemaglutide
Prof. Dr. Martin Wabitsch
Observational
70
Berlin, Leipzig, Ulm
2025-12-01
Not yet open
An Adaptive Open-label Multicentre Phase 1/2 Trial, to Determine the Recommended Phase 2 Dose of CCTx-001, and to Assess Safety, Tolerability, and Clinical Activity in Patients With Relapsed/Refractory Acute Myeloid Leukaemia
NCT06281847Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory
Advesya SAS
Phase 1/2
143
Munich, Ulm
2025-12
Recruiting
A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9
NCT07186842Advanced Solid Cancers
BioNTech SE
Phase 1/2
245
Bochum, München, Ulm
2025-11-18
Recruiting
International Genetic Obesity Registry
NCT07296900Genetic Obesity
University of Ulm
Observational
5,000
Ulm
2025-11-17
Recruiting
LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis:
NCT07186101Ulcerative Colitis
DrugsZotemtegrast·Mirikizumab
Eli Lilly and Company
Phase 2
252
Berlin, Dachau, Erlangen, Regensburg, Ulm
2025-11-10
Recruiting
A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma
NCT07015242Lymphoma
DrugsProcarbazine·Breyanzi·Calcium folinate·Temozolomide
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 2
65
Freiburg im Breisgau, Ulm, Cologne, Essen, Chemnitz, Berlin, Göttingen, Hamburg
2025-11-06
Recruiting
Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD)
NCT07007065Neovascular Age-related Macular Degeneration
DrugSurabgene Lomparvovec
AbbVie
Phase 3
561
Freiburg im Breisgau, Tübingen, Ulm, Munich, Göttingen, Hanover, Bonn, Ludwigshafen am Rhein
2025-11-05
Recruiting
A Study to Investigate the Efficacy and Safety of SAR444336 in Adults With Microscopic Colitis in Clinical Remission
NCT07156175Microscopic Colitis
Sanofi
Phase 2
54
Frankfurt, Ludwigshafen, Tübingen, Ulm
2025-10-14
Recruiting
An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis
NCT07184996Ulcerative Colitis
DrugDuvakitug
Sanofi
Phase 3
980
Berlin, Herne, Kiel, Leipzig, Minden, Ulm
2025-10-08
Recruiting
An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
NCT07184931Crohn's Disease
DrugDuvakitug
Sanofi
Phase 3
980
Tübingen, Ulm, Würzburg, Remscheid, Ludwigshafen am Rhein, Dresden, Leipzig, Jerichow
2025-10-01
Recruiting
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
NCT07028853Metastatic Castration Sensitive Prostate Cancer (mCSPC), Hormone Sensitive Prostate Cancer, Prostate Cancer, Cancer of the Prostate
DrugsMevrometostat·Xtandi·Enzalutamide
Pfizer
Phase 3
1,000
Heidelberg, Nürtingen, Ulm, Mettmann, Lübeck, Berlin, Düsseldorf, Hamburg
2025-09-28
Recruiting
A 52-week Study of Rilzabrutinib Efficacy and Safety Compared to Placebo in Adults Diagnosed With IgG4-related Disease
NCT07190196Immunoglobulin G4 Related Disease
DrugRilzabrutinib
Sanofi
Phase 3
124
Berlin, Erlangen, Hanover, Minden, Ulm
2025-09-26
Recruiting
Usnoflast Neuromuscular Investigation for Treatment Efficacy in Amyotrophic Lateral Sclerosis
NCT07023835Amyotrophic Lateral Sclerosis (ALS)
Zydus Therapeutics Inc.
Phase 2
240
Dresden, Hanover, Jena, Lübeck, Rostock, Ulm
2025-09-17
Recruiting
A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
NCT06973187Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
DrugsTacabrutideg·Pirtobrutinib
BeOne Medicines
Phase 3
500
Bochum, Bonn, Cologne, Dortmund, Karlsruhe, Lübeck, Stuttgart, Ulm
2025-09-04
Recruiting
Immunoadsorption for Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
NCT07154524Chronic Inflammatory Demyelinating Polyneuropathy
University of Ulm
Observational
140
Ulm
2025-08-27
Recruiting
A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Patients With Invasive Mold Infections.
NCT06925321Invasive Mold Infections
DrugFosmanogepix
Basilea Pharmaceutica
Phase 3
234
Ulm, Cologne, Mainz, Frankfurt
2025-08-26
By invitation
Transfemoral TAVI With or Without Coronary Angiogram in Patients With Severe Aortic Stenosis (PURE TAVI)
NCT06898086Severe Aortic Stenosis
Rede Optimus Hospitalar SA
Not applicable
620
Düsseldorf, Essen, Freiburg im Breisgau, Lübeck, Ulm
2025-08-08
Recruiting
German Registry of Alzheimer's Disease Treated With Transcranial Pulse Stimulation
NCT06313944Alzheimer Disease
Heinrich-Heine University, Duesseldorf
Observational
100
Potsdam, Oldenburg, Bonn, Neuss, Kempen, Ulm
2025-08-06
Recruiting
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
NCT07062965Breast Cancer
DrugsPrifetrastat·Exemestane·Everolimus·Fulvestrant
Pfizer
Phase 3
400
Ulm, Erlangen, Berlin, Hamburg
2025-08-05
Recruiting
A Study of LY4256984 in Participants With Sporadic Amyotrophic Lateral Sclerosis
NCT07100119ALS (Amyotrophic Lateral Sclerosis)
DrugLY4256984
Eli Lilly and Company
Phase 1
32
Lübeck, Rostock, Ulm
2025-08-05
Recruiting
A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)
NCT06911502Follicular Lymphoma
DrugsPrednisone/Prednisolone·Golcadomide·Bendamustine·Vincristine
Celgene
Phase 3
400
Ulm, Augsburg, Göttingen, Dortmund, Düsseldorf, Münster, Homburg, Erfurt
2025-07-28
Recruiting
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
NCT06758401Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Carcinoma, Non-Small-Cell Lung (NSCLC)
DrugsSigvotatug vedotin·Pembrolizumab
Pfizer
Phase 3
714
Ulm, Gröbenzell, Traunstein, Giessen, Kassel, Koblenz, Chemnitz, Halle
2025-07-23
Recruiting
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)
NCT06976203Alzheimer's Disease
DrugsKarX-EC·KarXT
Bristol-Myers Squibb
Phase 3
586
Munich, Göttingen, Bad Homburg, Chemnitz, Cologne, Ulm
2025-07-21
Recruiting
A Study Investigating the Effectiveness and Safety of Garadacimab for Treating Patients With Hereditary Angioedema (HAE)
NCT07001280Hereditary Angioedemas
CSL Behring
Observational
200
Ulm, Frankfurt am Main, Hanover, Leipzig, Hamburg, Berlin
2025-07-21
Recruiting
Fecal Microbiota Transfer in Liver Cancer to Overcome Resistance to Atezolizumab/Bevacizumab (FLORA)
NCT05690048Immunotherapy, HCC - Hepatocellular Carcinoma
DrugsVancomycin·Atezolizumab·Bevacizumab
Michael Dill
Phase 2
48
Heidelberg, Augsburg, Essen, Mannheim, Regensburg, Tübingen, Ulm
2025-07-16
Recruiting
A Study to Investigate the Efficacy and Safety of SAR442970 in Adult Participants With Ulcerative Colitis
NCT06975722Ulcerative Colitis
DrugBrivekimig
Sanofi
Phase 2
99
Minden, Kiel, Ulm
2025-07-07
Recruiting
A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)
NCT06863272Castration-Resistant Prostatic Cancer, Metastasis
DrugsOpevesostat·Ifinatamab Deruxtecan·Abiraterone·Enzalutamide
Merck Sharp & Dohme LLC
Phase 1/2
360
Heidelberg, Ulm, Jena, Hamburg
2025-07-03
Recruiting
Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.
NCT06846281Relapsing Multiple Sclerosis
DrugsRemibrutinib·Ocrelizumab
Novartis Pharmaceuticals
Phase 3
400
Berlin, Bochum, Erbach im Odenwald, Essen, Greifswald, Heidelberg, Münster, Ulm
2025-06-23
Active, closed
A Study to Assess Safety, Cellular Kinetics and Exploratory Efficacy of Rapcabtagene Autoleucel in Rheumatoid Arthritis and Sjogren's Disease
NCT07048197Rheumatoid Arthritis (RA) and Sjögren's Disease (SjD)
DrugRapcabtagene autoleucel
Novartis Pharmaceuticals
Phase 1/2
27
Freiburg im Breisgau, Göttingen, Cologne, Berlin, Ulm
2025-06-20
Recruiting
Long-term Characterization of GORE® TAG® Conformable Thoracic Stent Graft With ACTIVE CONTROL System Performance
NCT06658730Vascular Disease, Dissection, Dissection Aortic Aneurysm, Dissection of Aorta
W.L.Gore & Associates
Observational
1,500
Bonn, Frankfurt, Regensburg, Ulm
2025-06-19
Active, closed
A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab
NCT06880744Ulcerative Colitis
DrugsRisankizumab·Vedolizumab
AbbVie
Phase 3
573
Freiburg im Breisgau, Ulm, Dachau, Erlangen, Regensburg, Frankfurt am Main, Essen, Minden
2025-06-17
Recruiting
A Study to Evaluate Del-brax (Also Referred to as AOC 1020) in Participants With FSHD
NCT07038200Facioscapulohumeral Muscular Dystrophy, FSHD, FSHD - Facioscapulohumeral Muscular Dystrophy, FSHD1
DrugDel-brax
Avidity Biosciences, Inc.
Phase 3
200
Bonn, Göttingen, München, Ulm
2025-06-10
Recruiting
A Study to Investigate Efficacy and Safety of SAR442970 in Patients With Crohn's Disease
NCT06958536Crohn's Disease
DrugBrivekimig
Sanofi
Phase 2
99
Minden, Jena, Kiel, Ulm
2025-06-03
Recruiting
A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis
NCT07012395Ulcerative Colitis, Inflammatory Bowel Diseases, Colitis, Colitis, Ulcerative
DrugsSPY001·SPY002·SPY003
Spyre Therapeutics, Inc.
Phase 2
645
Berlin, Brandenburg an der Havel, Dachau, Frankfurt am Main, Kiel, Leipzig, Munich, Ulm
2025-05-27
Recruiting
Understanding Individual Variability in Neuronal Signal Transmission to Target Organs in Health and Disease
NCT06912048Autonomic Function
University of Ulm
Not applicable
52
Ulm
2025-05-14
Active, closed
A Study to Test Whether Treatment With BI 770371 in Combination With Pembrolizumab With or Without Cetuximab Helps People With Head and Neck Cancer Compared With Pembrolizumab Alone
NCT06806852Head and Neck Squamous Cell Carcinoma
DrugsBI 770371·Cetuximab·Pembrolizumab
Boehringer Ingelheim
Phase 1
91
Braunschweig, Jena, Leipzig, Ulm
2025-05-14
Recruiting
A Study to Compare TAK-881 and HYQVIA in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
NCT06747351Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
DrugsTAK-881·Hyqvia
Takeda
Phase 3
59
Mannheim, Ulm, Marburg, Hanover, Berlin
2025-05-06
Recruiting
Study to Assess Real Life Effectiveness of Foslevodopa/Foscarbidopa in Adult German Participants at Initial Stages of Advanced Parkinson's Disease (EARLY-FOS)
NCT06916507Parkinson's Disease
AbbVie
Observational
125
Allensbach, Heidelberg, Tübingen, Ulm, Wolfach, Erlangen, Ingolstadt, Munich
2025-05-06
Recruiting
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
NCT06875310Carcinoma, Non-Small-Cell Lung
DrugsAdagrasib·Pemetrexed·Cisplatin·Carboplatin
Mirati Therapeutics Inc.
Phase 3
630
Esslingen am Neckar, Ulm, München, Frankfurt am Main, Giessen, Hanover, Oldenburg, Cologne
2025-04-24
Recruiting
A Randomized Secondary Adjuvant Treatment Intervention Study Comparing Trastuzumab-Deruxtecan to SOC Therapy in eBC Patients With Molecular Relapse
NCT06643585Breast Cancer
DrugTrastuzumab deruxtecan
Prof. Wolfgang Janni
Phase 3
180
Ulm
2025-04-22
Recruiting
A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
NCT06890884Lymphoma, Large B-Cell, Diffuse
DrugsRituximab Biosimilar·Zilovertamab vedotin·Polatuzumab Vedotin·Prednisolone
Merck Sharp & Dohme LLC
Phase 2
594
Stuttgart, Tübingen, Ulm, Erlangen, Munich, Würzburg, Frankfurt am Main, Kassel
2025-04-11
Recruiting
Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors
NCT06726148Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors, Extensive-stage Small Cell Lung Cancer
DrugsRibociclib·Fulvestrant
Novartis Pharmaceuticals
Phase 1/2
280
Freiburg im Breisgau, Heidelberg, Ulm
2025-04-03
Active, closed
A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Ulcerative Colitis
NCT06867094Colitis Ulcerative
DrugSAR441566
Sanofi
Phase 2
204
Berlin, Duisburg, Frankfurt, Hanover, Tübingen, Ulm
2025-03-28
Recruiting
Imeroprubart in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
NCT07032662Chronic Inflammatory Demyelinating Polyneuropathy
Immunovant Sciences GmbH
Phase 2
162
Berlin, Bochum, Essen, Tübingen, Ulm, Würzburg
2025-03-18
Recruiting
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
NCT06819878Moderately to Severely Active Crohns Disease
DrugAfimkibart
Hoffmann-La Roche
Phase 3
600
Berlin, Frankfurt, Halle, Hanover, Jena, Mannheim, Ulm
2025-03-17
Active, closed
A Study to Determine the Efficacy, Safety, and Durability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration
NCT06795048Neovascular Age-related Macular Degeneration (nAMD)
DrugsVabysmo·Faricimab
Hoffmann-La Roche
Phase 4
274
Frankfurt, Hanover, Münster, Ulm, Würzburg
2025-03-14
Recruiting
Hypercaloric PEG Nutrition in ALS to Sustain Energy Homeostasis
NCT06877143Amyotrophic Lateral Sclerosis (ALS)
University of Ulm
Not applicable
76
Ulm
2025-03-01
Active, closed
An Open-label Study to Assess the Safety, Efficacy, and Cellular Kinetics of YTB323 in Relapsing Multiple Sclerosis
NCT06617793Relapsing Multiple Sclerosis
DrugRapcabtagene autoleucel
Novartis Pharmaceuticals
Phase 1/2
28
Bochum, Essen, Mainz, Ulm
2025-02-24
Recruiting
Magnetic Resonance Imaging in Metabolic Diseases
NCT06709846Metabolic Diseases
University of Ulm
Observational
126
Ulm
2025-02-08
Active, closed
A Study Assessing Adverse Event and How Oral ABBV-453 Moves Through the Body in Adult Participants With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
NCT06291220Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
DrugsABBV-453·Obinutuzumab
AbbVie
Phase 1
4
Ulm, Halle, Kiel, Berlin, Hamburg
2025-01-27
Recruiting
A Phase 2 Efficacy and Safety Study of GAL-101, 2% Ophthalmic Solution in Non-foveal Geographic Atrophy Secondary to Non-neovascular AMD
NCT06659549Geographic Atrophy of the Macula
Galimedix Therapeutics Inc
Phase 2
110
Bonn, Freiburg im Breisgau, Hanover, Neubrandenburg, Tübingen, Ulm
2025-01-10
Active, closed
Phase 2 Study of Rapcabtagene Autoleucel in Myositis
NCT06665256Idiopathic Inflammatory Myopathies
DrugRapcabtagene autoleucel
Novartis Pharmaceuticals
Phase 2
21
Cologne, Leipzig, Jena, Aachen, Hamburg, Mainz, Nuremberg, Ulm
2024-12-17
Active, closed
Study of ARO-ATXN2 Injection in Adults With Spinocerebellar Ataxia Type 2
NCT06672445Spinocerebellar Ataxia Type 2
Arrowhead Pharmaceuticals
Phase 1
39
Tübingen, Ulm
2024-12-17
Recruiting
Ivosidenib Plus Durvalumab and Gemcitabine/Cisplatin as First-Line Therapy in Participants With Locally Advanced or Metastatic Cholangiocarcinoma With an IDH1 Mutation
NCT06501625Locally Advanced, Unresectable or Metastatic Cholangiocarcinoma With an IDH1 Mutation
DrugsIvosidenib·Durvalumab·Gemcitabine·Cisplatin
Institut de Recherches Internationales Servier
Phase 1/2
52
Berlin, Düsseldorf, Frankfurt, Hanover, Ulm
2024-12-16
Active, closed
The Importance of Insulin Action in the Brain for the Immune System During Physical Activity
NCT06552130Insulin Sensitivity
University of Ulm
Not applicable
20
Ulm
2024-12-15
Active, closed
Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
NCT06608927Metastatic Pancreatic Ductal Adenocarcinoma
DrugsQuemliclustat·Nab-paclitaxel·Gemcitabine
Arcus Biosciences, Inc.
Phase 3
610
Bochum, Frankfurt am Main, Hamburg, Hanover, Heilbronn, Magdeburg, Riesa, Ulm
2024-12-13
Recruiting
An Extension Study to Assess Impact of Multiple Sclerosis (MS) on Physical Function and Provide Continued Ocrelizumab Treatment
NCT06675955Multiple Sclerosis
DrugOcrelizumab
Hoffmann-La Roche
Phase 3
500
Ulm, Westerstede, Wiesbaden
2024-12-13
Active, closed
Open-label, Multi-center, Phase I/II Study to Assess Safety, Disease Progression and Cellular Kinetics Following YTB323 Administration in Participants With Non-active Progressive Multiple Sclerosis (PMS)
NCT06675864Progressive Multiple Sclerosis
DrugRapcabtagene autoleucel
Novartis Pharmaceuticals
Phase 1/2
28
Essen, Mainz, Ulm
2024-12-12
Recruiting
A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Participants With Candidemia and/or Invasive Candidiasis.
NCT05421858Candidemia, Candidiasis, Invasive
DrugsCaspofungin·Fosmanogepix·Fluconazole
Basilea Pharmaceutica
Phase 3
450
Ulm, Regensburg, Frankfurt am Main, Giessen, Cologne, Heidelberg
2024-12-11
Recruiting
Fertility Protection for Children, Adolescents and Young Adults
NCT06692868Stem Cell Transplant, Stem Cell Transplantation, Oncological Outcomes, Oncological Patients
University of Ulm
Observational
2,000
Ulm
2024-12-09
Recruiting
A Study to Investigate Safety and Effectiveness of Tacabrutideg (BGB-16673) in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies
NCT06634589B-cell Malignancy, Relapsed Cancer, Refractory Cancer, B-cell Lymphoma
DrugsTacabrutideg·Mosunetuzumab·Sonrotoclax·Glofitamab
BeOne Medicines
Phase 1/2
80
Dresden, Jena, Kiel, Tübingen, Ulm
2024-11-27
Active, closed
Physiological Reaction After Food Intake
NCT06548165Physiological Reactivity to Cues
University of Ulm
Not applicable
36
Ulm
2024-11-12
Recruiting
A Comparison Study of Persistence of UPadacitinib vs. TNF-inhibitoRs In a German Real-world SettING
NCT06712628Moderate to Severe Rheumatoid Arthritis
AbbVie
Observational
678
Freiburg im Breisgau, Heidelberg, Tübingen, Ulm, Amberg, Augsburg, Marktredwitz, Munich
2024-11-07
Recruiting
A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy
NCT06541704Age-related Macular Degeneration (AMD), Geographic Atrophy (GA)
DrugsCemdisiran·Pozelimab
Regeneron Pharmaceuticals
Phase 3
975
Ulm, Berlin, Frankfurt am Main, Marburg, Neubrandenburg, Bonn, Düsseldorf, Münster
2024-10-30
Active, closed
Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
NCT06625320Pancreatic Cancer, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma
DrugsLiposomal Irinotecan·Leucovorin·Irinotecan·Adrucil
Revolution Medicines, Inc.
Phase 3
500
Berlin, Heidelberg, München, Ulm
2024-10-16
Recruiting
A Study to Evaluate ALN-HTT02 in Adult Patients With Huntington's Disease
NCT06585449Huntington's Disease
Alnylam Pharmaceuticals
Phase 1
66
Berlin, Bochum, Bonn, Dresden, Münster, Taufkirchen, Ulm
2024-10-14
Recruiting
NeoAdj. Therapy Comparing Sacituzumab Govitecan (SG) vs. SG+Pembrolizumab in Low-risk, Triple-neg. EBC (ADAPT-TN-III)
NCT06081244Triple Negative Breast Cancer
DrugsSacituzumab Govitecan·Keytruda·Pembrolizumab
Women's Cancer Study Group GmbH
Phase 3
348
Baden-Baden, Böblingen, Freiburg im Breisgau, Heilbronn, Tübingen, Ulm, Weinheim, Augsburg
2024-10-10
Active, closed
A Study to Evaluate IPN10200 Safety and Efficacy in the Prevention of Episodic or Chronic Migraine in Adults
NCT06625060Episodic Migraine, Chronic Migraine
DrugCorabotase
Ipsen
Phase 2
670
Berlin, Dresden, Essen, Frankfurt, Gera, Göppingen, Greifswald, Ulm
2024-10-10
Recruiting
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
NCT06561386Non-small Cell Lung Cancer
DrugsRelatlimab·Pemetrexed·Nivolumab·Cisplatin
Bristol-Myers Squibb
Phase 3
1,000
Esslingen am Neckar, Ulm, Kempten (Allgäu), München, Marburg, Hanover, Dortmund, Herne
2024-10-07
Recruiting
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
NCT06492616Breast Cancer
DrugsElacestrant·Tamoxifen·Exemestane·Anastrozole
Stemline Therapeutics, Inc.
Phase 3
4,220
Mannheim, Ulm, Augsburg, Eggenfelden, Erlangen, München, Regensburg, Rüdersdorf
2024-09-27
Recruiting
A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.
NCT06542250B-cell Malignancies
DrugAZD5492
AstraZeneca
Phase 1/2
174
Göttingen, München, Ulm, Würzburg
2024-09-18
Active, closed
A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 Melanoma
NCT06190951Melanoma
DrugsFianlimab·Cemiplimab
Regeneron Pharmaceuticals
Phase 2
151
Freiburg im Breisgau, Ulm, Munich, Regensburg, Würzburg, Giessen, Buxtehude, Bochum
2024-09-18
Recruiting
French-German Cohort Study to Determine Factors Associated With Weight Loss in Amyotrophic Lateral Sclerosis
NCT06147843Amyotrophic Lateral Sclerosis
University Hospital, Limoges
Not applicable
1,000
Hanover, Ulm
2024-09-17
Active, closed
STEP TEENS Weight Maintenance: A Research Study on How Well Semaglutide Helps Teenagers With Excess Body Weight to Lose Weight and Maintain Weight Loss
NCT06571383Obesity
DrugSemaglutide
Novo Nordisk A/S
Phase 4
500
Bochum, Göttingen, Hanover, Leipzig, Ulm
2024-09-17
Recruiting
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
NCT06548542Crohn's Disease
DrugsABBV-8736·Trosunilimab·Lutikizumab·Risankizumab
AbbVie
Phase 2
590
Freiburg im Breisgau, Mannheim, Ulm, Erlangen, Munich, Regensburg, Frankfurt am Main, Fulda
2024-09-04
Recruiting
ATLAS (AltaValve) Pivotal Trial
NCT06465745Mitral Regurgitation, Mitral Insufficiency, Mitral Valve Incompetence, Mitral Valve Regurgitation
4C Medical Technologies, Inc.
Not applicable
450
Berlin, Bonn, Cologne, Dortmund, Mainz, Oeynhausen, Trier, Ulm
2024-09-03
Active, closed
Phase IIa Study Evaluating AZD7798 in Crohn's Disease
NCT06450197Moderate to Severe Crohn's Disease
DrugAZD7798
AstraZeneca
Phase 2
120
Berlin, Potsdam, Ulm
2024-08-28
Recruiting
First in Human (FIH) Study of ALN-SOD in Adult Participants With Amyotrophic Lateral Sclerosis Associated With Mutation in the SOD1 Gene (SOD1-ALS)
NCT06351592Amyotrophic Lateral Sclerosis (ALS), Mutation in the Superoxide Dismutase-1 (SOD1) Gene
Regeneron Pharmaceuticals
Phase 1/2
54
Ulm
2024-08-28
Active, closed
Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26)
NCT06486441Endometrial Cancer
DrugsAdriamycin·Sacituzumab Govitecan·Taxol·Doxorubicin
Gilead Sciences
Phase 3
640
Bad Homburg, Düsseldorf, Essen, Hamburg, Hanover, Leipzig, München, Ulm
2024-08-28
Recruiting
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer
NCT06435429Metastatic HER2-positive Breast Cancer
DrugsZanidatamab·Vinorelbine·Eribulin·Trastuzumab
Jazz Pharmaceuticals
Phase 3
550
Berlin, Dortmund, Dresden, München, Ulm
2024-08-13
Active, closed
Study Protocol for a Pilot Randomized Controlled Trial of a Psychosocial Care Intervention in Intensive Care
NCT06733493Psychosocial Intervention, Intensive Care Units (ICUs), Psychosocial Health
Harald Gündel
Not applicable
375
Ulm, Magdeburg, Berlin
2024-08-01
By invitation
Long-term Safety and Tolerability of BHV-7000
NCT06443463Focal Epilepsy
DrugOpakalim
Biohaven Therapeutics Ltd.
Phase 2
660
Freiburg im Breisgau, Kehl, Ulm, Erlangen, München, Bernau bei Berlin, Marburg, Osnabrück
2024-07-30
Recruiting
Clinical Performance of the New Plasma Filter PX2 in TPE Treatments
NCT06382675Autoimmune Diseases
Fresenius Medical Care Deutschland GmbH
Not applicable
46
Aschaffenburg, Munich, Braunschweig, Paderborn, Berlin, Ulm, Würzburg
2024-07-18
Recruiting
Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen
NCT06127407Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1 Systemic Treatment Regimen
DrugIvosidenib
Servier Bio-Innovation LLC
Phase 3
136
Bad Saarow, Berlin, Dresden, Hamburg, Mannheim, München, Münster, Ulm
2024-07-09
Recruiting
Comparative Study of Navigation-assisted OrthoPilot® Elite and Robotic-assisted MAKO® Total Knee Arthroplasty
NCT05980442Osteoarthritis, Knee, Joint Diseases, Rheumatoid Arthritis of Knee, Posttraumatic Arthropathy
Aesculap AG
Observational
140
Ulm
2024-07-03
Recruiting
Intracoronary Stenting and Additional Results Achieved by ShockWAVE Coronary Lithotripsy
NCT06369142Coronary Artery Disease
Deutsches Herzzentrum Muenchen
Not applicable
666
Heidelberg, Mannheim, Singen, Ulm, Augsburg, Dachau, Erding, Ingolstadt
2024-07-01
Recruiting
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
NCT06324357Metastatic Breast Cancer, Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma
DrugsZongertinib·Zanidatamab·Trastuzumab emtansine·MFOLFOX6
Boehringer Ingelheim
Phase 1/2
768
Dresden, Erlangen, Essen, Hamburg, Mannheim, Ulm
2024-06-28
Recruiting
Non Interventional German Leptomeningeal Disease Register
NCT06146010Meningeal Neoplasms, Leptomeningeal Disease
University Hospital Tuebingen
Observational
50
Bonn, Mannheim, München, Münster, Siegen, Tübingen, Ulm
2024-06-26
Recruiting
Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)
NCT06463587Generalized Myasthenia Gravis
DrugCladribine
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Phase 3
264
Ulm, Göttingen, Hanover, Bochum, Düsseldorf, Dresden, Leipzig, Lübeck
2024-06-25
Active, closed
Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma
NCT06356129Large B-cell Lymphoma
DrugsGolcadomide·Vincristine·Doxorubicin·Prednisone
Celgene
Phase 3
850
Ulm, Augsburg, Bayreuth, Erlangen, Langen, Hanover, Koblenz, Halle
2024-06-19
Recruiting
Study of SRP-1001 in Adult and Adolescent Participants With Facioscapulohumeral Muscular Dystrophy Type 1
NCT06131983Muscular Dystrophy, Facioscapulohumeral
Sarepta Therapeutics, Inc.
Phase 1/2
60
München, Ulm
2024-06-19
Recruiting
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
NCT06430801Crohn's Disease
DrugTulisokibart
Merck Sharp & Dohme LLC
Phase 3
1,200
Pforzheim, München, Ulm, Hanover, Lüneburg, Rostock, Cologne, Duisburg
2024-06-05
Recruiting
A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)
NCT06439277Obesity, Weight Gain
DrugTirzepatide
Eli Lilly and Company
Phase 3
300
Cologne, Leipzig, Ulm
2024-06-03
Recruiting
Long-term Follow-up of Children Born in the PETN Studies
NCT06534307Intrauterine Growth Restriction, Pentaerithrityl Teratnitrate in Pregnancy, Long-Term Effects to Children
Jena University Hospital
Observational
228
Tübingen, Ulm, München, Hanover, Bonn, Dresden, Leipzig, Halle
2024-06-01
Not yet open
Autologous Muscle Stem Cell Therapy for Treatment of Congenital Urinary Incontinence in Epispadias Patients
NCT04729582Urinary Incontinence, Epispadias, Male
Simone Spuler, MD
Phase 1/2
21
Regensburg, Ulm
2024-06
Recruiting
Evaluation of the Effects of a Nutritional Intervention of Ketogenic Medium-chain Triglycerides and B-vitamins on Cognitive Functioning in Older Adults With Mild Cognitive Impairment (COGNIKET-MCI)
NCT06347315Mild Cognitive Impairment
Société des Produits Nestlé (SPN)
Not applicable
380
Bayreuth, Böblingen, Erbach im Odenwald, Ulm
2024-05-24
Active, closed
A Study to Test Whether BI 764524 Helps People With an Eye Condition Called Diabetic Retinopathy
NCT06321302Diabetic Retinopathy
Boehringer Ingelheim
Phase 2
190
Bonn, Mainz, Neubrandenburg, Tübingen, Ulm
2024-05-15
Active, closed
Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy
NCT06309966Focal Epilepsy
DrugOpakalim
Biohaven Therapeutics Ltd.
Phase 2/3
390
Freiburg im Breisgau, Kehl, Ulm, Erlangen, Bernau bei Berlin, Marburg, Osnabrück, Bielefeld
2024-05-13
Recruiting
Texture and Color Enhancement Imaging (TXI) for Inflammation Assessment in Patients With Inflammatory Bowel Diseases
NCT06892990Inflammatory Bowel Diseases, Colitis, Ulcerative, Crohn Disease
University of Ulm
Not applicable
80
Ulm
2024-05-08
Active, closed
S095035 as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of MTAP
NCT06188702MTAP-deleted Solid Tumors
DrugTNG462
Servier Bio-Innovation LLC
Phase 1/2
60
Ulm
2024-04-29
Recruiting
Hilotherapy for Prevention of Chemotherapy-induced Peripheral Polyneuropathy
NCT06627348Equipment and Supplies
University of Ulm
Not applicable
150
Ulm
2024-04-17
Recruiting
European Larynx Organ Preservation Study (ELOS) [MK-3475-C44]
NCT06137378Squamous Cell Carcinoma of Head and Neck, Hypopharyngeal Squamous Cell Carcinoma, Laryngeal Squamous Cell Carcinoma Stage III, Laryngeal Squamous Cell Carcinoma Stage IV
DrugsKeytruda·Pembrolizumab
University of Leipzig
Phase 2
140
Mannheim, Ulm, München, Regensburg, Würzburg, Potsdam, Cologne, Leipzig
2024-04-17
Recruiting
Venetoclax Treatment (26 Cycles) With 6 Cycles or 12 Cycles of Epcoritamab in Patients With Relapsed or Refractory CLL or SLL
NCT05791409CLL/SLL
DrugsEpcoritamab·Venetoclax
Stichting Hemato-Oncologie voor Volwassenen Nederland
Phase 1/2
112
Berlin, Cologne, Freiburg im Breisgau, Greifswald, Münster, Stuttgart, Ulm
2024-04-10
Recruiting
A Study to Investigate Mechanisms of Resistance to Breast Cancer Therapies
NCT06274515Breast Cancer
Hoffmann-La Roche
Phase 4
320
Cologne, Essen, Karlsruhe, Mannheim, Ulm
2024-04-02
Active, closed
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis
NCT06254950Ulcerative Colitis
DrugZasocitinib
Takeda
Phase 2
213
Frankfurt am Main, Hamburg, Heidelberg, Kiel, Ludwigshafen, Tübingen, Ulm
2024-03-29
Active, closed
Study of GS-1427 in Participants With Moderately to Severely Active Ulcerative Colitis
NCT06290934Ulcerative Colitis
Gilead Sciences
Phase 2
228
Dresden, Halle, Kiel, Ulm
2024-03-27
Active, closed
A Study to Assess Adverse Events and Change in Disease Activity From Intravenous (IV) and Subcutaneous (SC) Lutikizumab in Adult Participants With Active Ulcerative Colitis
NCT06257875Ulcerative Colitis
DrugsLutikizumab·Humira·Adalimumab
AbbVie
Phase 2
156
Ulm, Munich, Ludwigshafen am Rhein, Leipzig, Kiel, Hamburg
2024-03-23
Recruiting
A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer
NCT06072781Low Grade Serous Ovarian Cancer
DrugsAvutometinib·Defactinib·Pegylated liposomal doxorubicin·Anastrozole
Verastem, Inc.
Phase 3
270
Frankfurt am Main, Berlin, Dresden, Essen, Hamburg, Mannheim, Ulm
2024-03-18
Active, closed
Relative Contribution of Brain Insulin Action for Postprandial Metabolism
NCT06295640Glucose Metabolism Disorders
University of Ulm
Not applicable
31
Ulm
2024-03-18
By invitation
ENVISION IDE Trial: Safety and Effectiveness of NAVITOR in Transcatheter Aortic Valve Implantation
NCT05932615Aortic Valve Stenosis, Heart Valve Diseases, Aortic Valve Disease, Heart Disease Structural Disorder
Abbott Medical Devices
Not applicable
1,500
Dortmund, Bad Nauheim, Cologne, Frankfurt, Kiel, München, Ulm
2024-03-15
Recruiting
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease
NCT06233461Crohn's Disease
DrugZasocitinib
Takeda
Phase 2
268
Frankfurt, Frankfurt am Main, Kiel, Ludwigshafen, Mannheim, Tübingen, Ulm
2024-03-05
Recruiting
Study of SRP-1003 in Participants With Type 1 Myotonic Dystrophy
NCT06138743Myotonic Dystrophy 1
Sarepta Therapeutics, Inc.
Phase 1/2
78
Munich, Ulm
2024-03-04
Active, closed
Predicting Neuromuscular Recovery in Surgical Patients Using Machine Learning
NCT05471882Residual Paralysis, Post Anesthesia, Postoperative Complications, Neuromuscular Blockade, Quantitative Neuromuscular Monitoring
University Hospital Ulm
Observational
240,000
Ulm, Munich
2024-03-01
Recruiting
Mentalization-based Treatment Versus Bona-fide Treatment for Patients With Borderline Personality Disorder in Germany
NCT06018272Borderline Personality Disorder
Heidelberg University
Not applicable
304
Berlin, Düsseldorf, Heidelberg, Jena, Ulm
2024-02-28
Recruiting
A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
NCT06161025Solid Cancer
DrugsR-DXd·Topotecan·Paclitaxel
Daiichi Sankyo
Phase 2/3
860
Dresden, Essen, Hamburg, Mannheim, Ulm
2024-02-27
Active, closed
Long-Term Safety, Tolerability and Efficacy of OMS906 in Paroxysmal Nocturnal Hemoglobinuria
NCT06298955Paroxysmal Nocturnal Hemoglobinuria
DrugOMS906 study drug
Omeros Corporation
Phase 2
25
Aachen, Ulm
2024-02-19
Recruiting
A Global Prospective Observational Registry of Patients With Pompe Disease
NCT06121011Pompe Disease
DrugsAlglucosidase alfa·Cipaglucosidase alfa·Miglustat·Avalglucosidase alfa
Amicus Therapeutics
Observational
500
Bochum, Höchheim, Marburg, München, Ulm
2024-02-16
Recruiting
Open-label Study to Evaluate Metreleptin in Patients With Partial Lipodystrophy
NCT06484868Partial Lipodystrophy
DrugMetreleptin
Amryt Pharma
Phase 4
12
Berlin, Ulm
2024-02-08
Recruiting
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
NCT06152575Multiple Myeloma
DrugsElotuzumab·Elranatamab·Carfilzomib·Pomalidomide
Pfizer
Phase 3
492
Freiburg im Breisgau, Stuttgart, Ulm, Nuremberg, Bonn, Berlin, Cottbus, Hamm
2024-02-08
Recruiting
NeoAdjuvant Therapy With Trastuzumab-deruxtecan Versus Chemotherapy+Trastuzumab+Pertuzumab in HER2+ Early Breast Cancer
NCT05704829HER2-positive Early Breast Cancer
DrugTrastuzumab deruxtecan
Women's Cancer Study Group GmbH
Phase 2
702
Baden-Baden, Freiburg im Breisgau, Tübingen, Ulm, Augsburg, Munich, Bremerhaven, Frankfurt am Main
2024-02-05
Recruiting
PROCARE - PROstate Cancer Real World Evidence Registry
NCT06835218Prostate Cancer, Biochemical Recurrence of Malignant Neoplasm of Prostate, Non-metastatic Castration-resistant Prostate Cancer, Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
UroTrials Company (GmbH)
Observational
5,000
Freiburg im Breisgau, Heidelberg, Mannheim, Nürtingen, Tübingen, Ulm, Augsburg, Bayreuth
2024-01-29
Recruiting
Phase 1 Study of Allo-RevCAR01-T-CD123 in Patients With Selected CD123 Positive Hematologic Malignancies (1b Dose Expansion)
NCT05949125Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory
AvenCell Europe GmbH
Phase 1
37
Ulm, Munich, Würzburg, Marburg, Dresden, Berlin, Cologne, Essen
2024-01-03
Recruiting
A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
NCT06136559Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
DrugsNemtabrutinib·Ibrutinib·Acalabrutinib
Merck Sharp & Dohme LLC
Phase 3
1,200
Ulm, Landshut, Mönchengladbach, Koblenz, Halle, Berlin
2023-12-13
Active, closed
Frexalimab in Preservation of Endogenous Insulin Secretion Compared to Placebo in Adults, Adolescents and Children on Top of Insulin Therapy (FABULINUS)
NCT06111586Type 1 Diabetes Mellitus
DrugFrexalimab
Sanofi
Phase 2
197
Dresden, Hanover, Oldenburg in Holstein, Ulm
2023-12-11
Active, closed
Study of Tilpisertib Fosmecarbil in Participants With Moderately to Severely Active Ulcerative Colitis
NCT06029972Ulcerative Colitis
Gilead Sciences
Phase 2
176
Berlin, Hanover, Kiel, Liepzig, Ulm
2023-12-05
Active, closed
A Study to Evaluate the Efficacy and Safety of Ropeginterferon Alfa-2b in Essential Thrombocythaemia Patients
NCT06514807Essential Thrombocythaemia
DrugBesremi
AOP Orphan Pharmaceuticals AG
Phase 3
117
Aachen, Halle, Hanover, Mannheim, Minden, Ulm
2023-12-04
Active, closed
A Study of Efficacy and Safety of Rosnilimab in Subjects With Moderate to Severe Ulcerative Colitis (ROSETTA)
NCT06127043Ulcerative Colitis
DrugRosnilimab
AnaptysBio, Inc.
Phase 2
132
Berlin, Brandenburg, Dachau, Duisburg, Erlangen, Hamburg, Kiel, Ulm
2023-12-04
Recruiting
Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation.
NCT05948943Lymphatic Malformations
DrugAlpelisib
Novartis Pharmaceuticals
Phase 2/3
232
Freiburg im Breisgau, Mannheim, Cologne, Leipzig, Berlin, Ulm
2023-11-24
Active, closed
A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES H&N-202
NCT06062420Neoplasms, Head and Neck
DrugsRemzistotug·Nelistotug·Belrestotug·Dostarlimab
GlaxoSmithKline
Phase 2
316
Frankfurt am Main, Essen, Aachen, Berlin, Giessen, Hamburg, Regensburg, Ulm
2023-11-14
Active, closed
Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil, Folinic Acid, and Bevacizumab
NCT06107413Unresectable Metastatic Colorectal Cancer
DrugsFolinic acid·Telisotuzumab Adizutecan·Fluorouracil·Irinotecan
AbbVie
Phase 2
280
Mannheim, Tübingen, Ulm, Dresden, Berlin, Hamburg
2023-11-12
Active, closed
A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001)
NCT06052059Ulcerative Colitis
DrugTulisokibart
Merck Sharp & Dohme LLC
Phase 3
1,020
Ulm, Dachau, Munich, Frankfurt am Main, Hanover, Lüneburg, Duisburg, Minden
2023-10-25
Recruiting
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
NCT06026410Solid Tumors With HRAS Alterations, Non Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC)
DrugsAdagrasib·Cabozantinib
Kura Oncology, Inc.
Phase 1
300
Berlin, Ulm, Würzburg
2023-10-18
Active, closed
A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation
NCT06045806Multiple Myeloma
DrugsIdecabtagene vicleucel·Endoxan·Fludara·Cytoxan
Celgene
Phase 3
79
Heidelberg, Ulm, Nuremberg, Cologne, Leipzig, Dresden, Essen, Hamburg
2023-10-16
Recruiting
Fracture Monitor - Femur
NCT05410587Femoral Fracture
AO Innovation Translation Center
Not applicable
37
Homburg, Münster, Tübingen, Ulm
2023-10-03
Active, closed
An Open Label Extension (OLE) Study to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)
NCT05900141Hyperlipoproteinemia (a)
DrugPelacarsen
Novartis Pharmaceuticals
Phase 3
41
Frankfurt am Main, Berlin, Cloppenburg, Dresden, Erlangen, Mainz, München, Ulm
2023-09-29
Active, closed
A Long-term Study of STAR-0215 in Participants With Hereditary Angioedema
NCT06007677Hereditary Angioedema
DrugNavenibart
Astria Therapeutics, Inc.
Phase 2
56
Berlin, Frankfurt, Ulm
2023-09-26
Active, closed
A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms
NCT05936359Myeloproliferative Neoplasms
DrugsINCA033989·Ruxolitinib
Incyte Corporation
Phase 1
160
Aachen, Halle, Ulm
2023-09-25
Active, closed
Does Electromyography Improve Precision and Reliability of Neuromuscular Monitoring in Paediatric Patients
NCT06062290Neuromuscular Blockade, Residual, Postoperative Complications
University Hospital Ulm
Observational
64
Ulm
2023-09-20
By invitation
A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Active Idiopathic Inflammatory Myopathy
NCT05979441Myositis, Active Idiopathic Inflammatory Myopathy, Dermatomyositis, Polymyositis
DrugEfgartigimod PH20
argenx
Phase 3
240
Berlin, Hamburg, Herne, Mannheim, Tübingen, Ulm
2023-09-12
Recruiting
Mosunetuzumab-Lenalidomide Versus Investigator Choices in Patients With Relapsed or Refractory Marginal Zone Lymphoma
NCT06006117Marginal Zone Lymphoma
DrugsMosunetuzumab·Bendamustine·Lenalidomide·Rituximab
The Lymphoma Academic Research Organisation
Phase 3
260
Amberg, Berlin, Kiel, Ludwigshafen, Regensburg, Stuttgart, Trier, Ulm
2023-09-05
Recruiting
Cardiac Biomarkers for the Quantification of Myocardial Damage After Cardiac Surgery
NCT06066970Cardiac Valve Disease
Jena University Hospital
Observational
100
Freiburg im Breisgau, Ulm, Münster, Halle, Jena
2023-09-05
Active, closed
An Extension Study to Evaluate the Long-Term Safety and Efficacy of Votoplam in Participants With Huntington's Disease (HD)
NCT06254482Huntington Disease
DrugVotoplam
Novartis Pharmaceuticals
Phase 2
144
Berlin, Bochum, Münster, Ulm
2023-08-25
Recruiting
IMA402 T Cell-Engaging Receptor Molecule (TCER®) in Recurrent and/or Refractory Solid Tumors
NCT05958121Refractory Cancer, Recurrent Cancer, Solid Tumor, Adult, Cancer
Immatics Biotechnologies GmbH
Phase 1/2
400
Heidelberg, Mannheim, Tübingen, Ulm, Erlangen, Nuremberg, Regensburg, Würzburg
2023-08-09
Active, closed
A Study of Tobemstomig + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer
NCT05852691Breast Cancer
DrugsTobemstomig·Nab-paclitaxel·Pembrolizumab
Hoffmann-La Roche
Phase 2
83
Essen, Langen, Ulm
2023-07-18
Active, closed
A Research Study on How Well Semaglutide Helps Children and Teenagers With Excess Body Weight Lose Weight
NCT05726227Obesity
DrugSemaglutide
Novo Nordisk A/S
Phase 3
210
Halle, Hanover, Leipzig, Ulm
2023-07-07
Recruiting
Genomics Guided Targeted Post-neoadjuvant Therapy in Patients With Early Breast Cancer (COGNITION-GUIDE)
NCT05332561Early-stage Breast Cancer
DrugsPhesgo·Ipatasertib·Inavolisib·Sacituzumab Govitecan
German Cancer Research Center
Phase 2
240
Heidelberg, Tübingen, Augsburg, Erlangen, Ulm, Würzburg, Dresden, Berlin
2023-06-29
Recruiting
Combination Treatment of Belantamab Mafodotin and Venetoclax in Treatment of Relapsed and Refractory t(11;14) Multiple Myeloma
NCT05853965Multiple Myeloma, Multiple Myeloma in Relapse
Universitätsklinikum Hamburg-Eppendorf
Phase 1/2
45
Hamburg, Chemnitz, Heidelberg, Lübeck, Ulm
2023-06-28
Recruiting
Improved Muscle Metabolism by Combination of Muscle Activation and Protein Substitution ( IMEMPRO )
NCT05919940ICU Acquired Weakness, Muscle Atrophy, Energy Malnutrition Protein, Quality of Life
Technical University of Munich
Not applicable
40
Munich, Berlin, Ulm
2023-06-27
Active, closed
A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma
NCT05827016Multiple Myeloma
DrugsIberdomide·Lenalidomide
Bristol-Myers Squibb
Phase 3
1,230
Ulm, Augsburg, Bayreuth, Erlangen, Munich, Cottbus, Hamburg, Chemnitz
2023-06-22
Active, closed
Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies
NCT05753501Hematologic Cancer
DrugVenetoclax
AbbVie
Phase 1
135
Ulm, Würzburg, Rostock, Homburg, Berlin, Hamburg
2023-06-09
Active, closed
Pembrolizumab and Lenvatinib After Definitive Chemoradiation of Locally Advanced HNSCC
NCT05433116Head and Neck Squamous Cell Carcinoma
DrugsLenvatinib·Keytruda·Pembrolizumab
Universität des Saarlandes
Phase 2
50
Ulm, Augsburg, Erlangen, Regensburg, Frankfurt am Main, Giessen, Düsseldorf, Homburg
2023-05-25
Recruiting
A Study to Understand How the Study Medicine (PF-06823859) Works in People With Active Idiopathic Inflammatory Myopathies [Dermatomyositis (DM) and Polymyositis (PM)]
NCT05895786Myositis
Pfizer
Phase 3
318
Ulm, Erlangen, München
2023-05-20
Recruiting
A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALL
NCT05748171ACUTE LYMPHOBLASTIC LEUKEMIA
DrugInotuzumab Ozogamicin
Pfizer
Phase 2
100
Freiburg im Breisgau, Ulm, Würzburg, Frankfurt am Main, Hanover, Essen, Münster, Kiel
2023-05-17
Recruiting
Immunoadsorption Versus Immunoglobulins for Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
NCT04881682CIDP
DrugImmunoglobulins
University of Ulm
Phase 2
20
Ulm
2023-05-01
Active, closed
A Trial of Setmelanotide in Acquired Hypothalamic Obesity
NCT05774756Hypothalamic Obesity
DrugSetmelanotide
Rhythm Pharmaceuticals, Inc.
Phase 3
143
Hamburg, München, Oldenburg, Ulm
2023-04-26
By invitation
An Open-label Study of XEN1101 in Epilepsy
NCT05718817Focal Epilepsy, Tonic-Clonic Seizures
DrugAzetukalner
Xenon Pharmaceuticals Inc.
Phase 3
880
Aachen, Bielefeld, Frankfurt, Freiburg im Breisgau, Marburg, München, Ulm
2023-04-25
Recruiting
PrEventing PostoPERative Pulmonary Complications by Establishing a MachINe-learning assisTed Approach
NCT05789953Postoperative Pulmonary Complications
Britta Trautwein
Observational
512
Ulm
2023-04-25
Active, closed
A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma
NCT05805501Renal Cell Carcinoma
DrugsTobemstomig·Tiragolumab·Axitinib·Keytruda
Hoffmann-La Roche
Phase 2
199
Dresden, Hamburg, Hanover, München, Nürtingen, Ulm
2023-04-21
Active, closed
A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma
NCT05572515Relapsed or Refractory Multiple Myeloma
DrugsTeclistamab·Carfilzomib·Pomalidomide·Bortezomib
Janssen Research & Development, LLC
Phase 3
614
Cottbus, Dresden, Greifswald, Hamburg, Heidelberg, Marburg, Tübingen, Ulm
2023-03-29
Recruiting
Tafasitamab (MOR00208) in Pediatric Patients With Relapsed or Refractory Acute B Lineage Leukemia
NCT05366218ALL, Childhood B-Cell, Acute Lymphoid Leukemia Relapse, Acute Lymphocytic Leukemia Refractory
DrugTafasitamab
University Hospital Tuebingen
Phase 1/2
20
Freiburg im Breisgau, Tübingen, Ulm, München, Hamburg, Düsseldorf, Berlin, Essen
2023-03-08
Active, closed
A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma
NCT05625399Melanoma
DrugsHyqvia·Relatlimab·Nivolumab
Bristol-Myers Squibb
Phase 3
579
Heidelberg, Ulm, Regensburg, Lübeck, Berlin, Buxtehude, Dortmund, Erfurt
2023-03-06
Active, closed
Safety and Efficacy Study of Viaskin Peanut in Peanut-allergic Children 4-7 Years of Age
NCT05741476Allergy, Peanut
DBV Technologies
Phase 3
600
Düsseldorf, Frankfurt, Ulm
2023-02-21
Recruiting
Transcatheter Mitral Valve Replacement in Patients With Severe Symptomatic Mitral Regurgitation - APOLLO-EU Trial
NCT05496998Mitral Regurgitation
Medtronic Cardiovascular
Not applicable
400
Bad Oeynhausen, Berlin, Bonn, Hamburg, Leipzig, Mainz, München, Ulm
2023-02-07
Active, closed
GENERATION HD2. A Study to Evaluate the Safety, Biomarkers, and Efficacy of Tominersen Compared With Placebo in Participants With Prodromal and Early Manifest Huntington's Disease
NCT05686551Huntington Disease
Hoffmann-La Roche
Phase 2
301
Aachen, Berlin, Bochum, Bonn, Erlangen, Lübeck, Taufkirchen, Ulm
2023-02-03
Recruiting
Clinical Value and Cost-effectiveness of a Personalized Prevention Program (PPP) in Patients With High Risk Stable CHD
NCT04433052Coronary Heart Disease
Tampere University
Not applicable
12,000
Berlin, Frankfurt, Mannheim, München, Ulm
2023-02-01
Active, closed
ABTECT - Maintenance
NCT05535946Ulcerative Colitis
DrugObefazimod
Abivax S.A.
Phase 3
1,116
Freiburg im Breisgau, Heidelberg, Nürtingen, Pforzheim, Tübingen, Ulm, Erlangen, Munich
2023-01-16
Active, closed
A Study to Evaluate the Long-Term Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn's Disease
NCT05668013Crohn Disease, Colitis, Ulcerative
DrugDuvakitug
Teva Branded Pharmaceutical Products R&D LLC
Phase 2
247
Kiel, Tübingen, Ulm, Wipperfürth
2023-01-11
Active, closed
A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)
NCT05552976Relapsed or Refractory Multiple Myeloma
DrugsMezigdomide·Carfilzomib·Dexamethasone
Bristol-Myers Squibb
Phase 3
606
Ulm, Munich, Hanover, Dortmund, Kiel, Jena, Berlin, Cologne
2023-01-10
Active, closed
A Phase 3 Study of Obexelimab in Patients With IgG4-Related Disease
NCT05662241IgG4 Related Disease
DrugObexelimab
Zenas BioPharma (USA), LLC
Phase 3
194
München, Ulm
2023-01-09
Active, closed
A Study to Assess Safety and Effectiveness of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis.
NCT05627362Primary Sclerosing Cholangitis
DrugElafibranor
Ipsen
Phase 2
68
Berlin, Frankfurt, Heidelberg, Ulm
2022-12-29
Active, closed
A Study Evaluating the Safety and Tolerability of QRL-201 in ALS
NCT05633459Amyotrophic Lateral Sclerosis
QurAlis Corporation
Phase 1
69
Bonn, Berlin, Lübeck, Ulm
2022-12-16
Active, closed
Myocardial Protection in Patients With Post-acute Inflammatory Cardiac Involvement Due to COVID-19
NCT05619653COVID-19 Associated Cardiac Involvement, Remodeling, Left Ventricle, Remodeling, Vascular, Left Ventricular Dysfunction
DrugsLosartan·Prednisolone
Valentina Puentmann
Phase 3
279
Frankfurt am Main, Greifswald, Kiel, Ulm
2022-12-12
Recruiting
Response Prediction of Hyperthermic Intraperitoneal Chemotherapy in Gastro- Intestinal Cancer
NCT05652348Gastric Cancer, Colon Cancer, Peritoneal Carcinomatosis
Technische Universität Dresden
Observational
48
Berlin, Cologne, Dresden, Ulm, Würzburg
2022-12-08
Recruiting
PROOFS-Registry - Premenopausal Women With Breast Cancer Optimally Treated With OFS
NCT05792150Female Breast Cancer
Women's Cancer Study Group GmbH
Observational
1,470
Baden-Baden, Pforzheim, Stuttgart, Ulm, Weinheim, Karlsruhe, Ravensburg, Amberg
2022-12-07
Recruiting
Standard Surveillance vs. Intensive Surveillance in Early Breast Cancer
NCT05658172Breast Cancer
Prof. Wolfgang Janni
Not applicable
3,500
Ulm
2022-12-07
Active, closed
Dose-finding Study of SAR443122 in Adult Participants With Ulcerative Colitis
NCT05588843Colitis Ulcerative
Sanofi
Phase 2
187
Düsseldorf, Fulda, Kiel, Ludwigshafen, Ulm
2022-11-25
Active, closed
A Study to Evaluate MORF-057 in Adults With Moderately to Severely Active UC
NCT05611671Inflammatory Bowel Diseases, Colitis, Ulcerative
DrugZotemtegrast
Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)
Phase 2
280
Berlin, Kiel, Ulm
2022-11-21
Active, closed
Dazucorilant in Patients With Amyotrophic Lateral Sclerosis
NCT05407324Amyotrophic Lateral Sclerosis
Corcept Therapeutics
Phase 2
279
Berlin, Bonn, Dresden, Hanover, Jena, München, Rostock, Ulm
2022-11-15
Recruiting
A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
NCT05623020Multiple Myeloma
DrugsElranatamab·Bortezomib·Daratumumab·Lenalidomide
Pfizer
Phase 3
1,060
Freiburg im Breisgau, Tübingen, Ulm, Mainz, Aachen, Braunschweig, Chemnitz, Hamburg
2022-11-10
Active, closed
A Study of Bleximenib in Combination With Acute Myeloid Leukemia (AML) Directed Therapies
NCT05453903Leukemia, Myeloid, Acute
DrugsBleximenib·Idarubicin·Daunorubicin·Cytarabine
Janssen Research & Development, LLC
Phase 1
196
Berlin, Dresden, Heidelberg, Leipzig, Ulm
2022-10-04
Active, closed
A Study of Guselkumab in Participants With Fistulizing, Perianal Crohn's Disease
NCT05347095Fistulizing Crohns Disease, Perianal Crohns Disease
DrugGuselkumab
Janssen-Cilag Ltd.
Phase 3
288
Berlin, Frankfurt, Kiel, Mannheim, Ulm
2022-09-27
Recruiting
Registry to Collect Data on Patients Undergoing Segmental Mandibular Defect Reconstruction Following Oral Squamous Cell Carcinoma Resection and Drugs-induced Osteonecrosis
NCT04098146Mandibular Reconstruction, Segmental Mandibular Defects
AO Innovation Translation Center
Observational
300
Tübingen, Aachen, Berlin, Hanover, Heidelberg, Leipzig, Munich, Ulm
2022-09-12
Recruiting
A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma
NCT05548296Endometrial Adenocarcinoma
DrugGemcitabine
Acrivon Therapeutics
Phase 2
350
Essen, Münster, Ulm
2022-08-29
Active, closed
A Study to Learn About the Safety of Diranersen (BIIB080) Injections and Whether They Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD Dementia Between 50 to 80 Years of Age
NCT05399888Mild Cognitive Impairment Due to Alzheimer's Disease, Alzheimer's Disease Dementia
Biogen
Phase 2
416
Mannheim, Tübingen, Ulm, Bayreuth, München, Erbach im Odenwald, Göttingen, Bonn
2022-08-24
Active, closed
Comprehensive Analysis of Predictors of the Treatment With Pembrolizumab and Olaparib in Patients With Unresectable or Metastatic HER2 Negative Breast Cancer and a Deleterious Germline Mutation or a Homologous Recombination Deficiency (COMPRENDO
NCT05033756Malignant Neoplasm of Breast, Breast Cancer
DrugsOlaparib·Keytruda·Pembrolizumab
Institut fuer Frauengesundheit
Phase 2
11
Tübingen, Ulm, Erlangen, Bottrop, Düsseldorf, Berlin
2022-07-30
Recruiting
A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
NCT05254743Chronic Lymphocytic Leukemia, Leukemia, Lymphocytic, Leukemia, B-cell, Small Lymphocytic Lymphoma
DrugsPirtobrutinib·Ibrutinib
Loxo Oncology, Inc.
Phase 3
737
Dortmund, Dresden, Ulm
2022-07-22
Recruiting
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ION464 Administered to Adults With Multiple System Atrophy (HORIZON)
NCT04165486Multiple System Atrophy
Ionis Pharmaceuticals, Inc.
Phase 1
40
Ulm, Düsseldorf, Göttingen, Hanover, Marburg, München
2022-07-21
Active, closed
A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)
NCT05458297Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Follicular Lymphoma, Richter Transformation Lymphoma
DrugsZilovertamab vedotin·Nemtabrutinib
Merck Sharp & Dohme LLC
Phase 2
189
Ulm, Cologne
2022-07-21
Active, closed
STAR-LIFE: a Post-market Registry on MINIject
NCT05269680Open Angle Glaucoma
iSTAR Medical
Observational
320
Bochum, Düsseldorf, Hamburg, Kiel, Lübeck, Ulm
2022-07-20
Active, closed
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
NCT05283720Non-Hodgkin Lymphoma
DrugsGolcadomide·Polatuzumab Vedotin·Epcoritamab·Doxorubicin Hydrochloride
Genmab
Phase 2
264
Ulm, Augsburg, Regensburg, Würzburg, Marburg, Leipzig
2022-06-14
Recruiting
A Long-term, Post-marketing Safety Study of Palynziq in Patients With PKU (PALace)
NCT05813678Phenylketonuria (PKU)
DrugPegvaliase
BioMarin Pharmaceutical
Observational
450
Cottbus, Hamburg, Leipzig, Mainz, Münster, Ulm
2022-06-06
Recruiting
MiECC Versus Conventional Cardiopulmonary Bypass in Cardiac Surgery (MiECS)
NCT05487612Coronary Artery Disease, Aortic Valve Stenosis, Extracorporeal Circulation; Complications
Aristotle University Of Thessaloniki
Not applicable
1,300
Coswig, Göttingen, Ulm
2022-05-26
Active, closed
IMA401 TCER® in Recurrent and/or Refractory Solid Tumors, Alone or in Combination With a Checkpoint Inhibitor
NCT05359445Refractory Cancer, Recurrent Cancer, Solid Tumor, Adult, Cancer
DrugsKeytruda·Pembrolizumab
Immatics Biotechnologies GmbH
Phase 1
95
Freiburg im Breisgau, Heidelberg, Tübingen, Ulm, Erlangen, Munich, Nuremberg, Regensburg
2022-05-19
Recruiting
German Dementia Registry
NCT07433010Dementia Disorder
RWTH Aachen University
Observational
5,000
Heidelberg, Mannheim, Tübingen, Ulm, Erlangen, Frankfurt (Oder), Rüdersdorf, Hamburg
2022-05-16
Active, closed
A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis
NCT05269004Multiple Sclerosis
DrugOcrelizumab
Hoffmann-La Roche
Phase 3
1,300
Tübingen, Ulm, Bayreuth, Munich, Westerstede, Düsseldorf, Chemnitz, Leipzig
2022-05-03
Active, closed
A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)
NCT05288166Prostatic Neoplasms, Neoplasm Metastasis, Urogenital Neoplasms, Physiological Effects of Drugs
DrugsAbiraterone·Abemaciclib·Prednisolone·Prednisone
Eli Lilly and Company
Phase 3
925
Freiburg im Breisgau, Heidelberg, Nürtingen, Ulm, Tübingen, Munich, Frankfurt am Main, Duisburg
2022-04-14
Active, closed
Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer
NCT05316155Non-Muscle Invasive Bladder Neoplasms
DrugErdafitinib
Janssen Research & Development, LLC
Phase 1/2
235
Dresden, Duisburg, Frankfurt am Main, Herne, Mettmann, Münster, Ulm
2022-04-11
Recruiting
Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)
NCT04895436Chronic Lymphocytic Leukemia (CLL)
DrugsVenclexta·Obinutuzumab·Venetoclax
AbbVie
Phase 2
75
Mutlangen, Ulm, Landshut, Munich, Rostock, Cologne, Homburg, Dresden
2022-03-28
Active, closed
MaaT013 As Salvage Therapy in Ruxolitinib Refractory GI-aGVHD Patients
NCT04769895Acute Graft Versus Host Disease in Intestine, Steroid Refractory GVHD
MaaT Pharma
Phase 3
66
Berlin, Mannheim, Regensburg, Ulm, Würzburg
2022-03-25
Active, closed
A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma
NCT05100862Relapsed/Refractory Follicular Lymphoma, Marginal Zone Lymphoma
DrugsZanubrutinib·Obinutuzumab·Lenalidomide·Rituximab
BeOne Medicines
Phase 3
799
Essen, Ulm
2022-03-10
Active, closed
A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer
NCT05132582HER2 Positive Breast Cancer
DrugsPerjeta·Tucatinib·Herceptin·Pertuzumab
Seagen, a wholly owned subsidiary of Pfizer
Phase 3
654
Münster, Manheim, Mannheim, Augsburg, Berlin, Hamburg, München, Ulm
2022-03-07
Recruiting
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia
NCT05091424Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
DrugsMosunetuzumab·Venclyxto·Venclexta·Tocilizumab
Hoffmann-La Roche
Phase 1
332
Augsburg, Cologne, Ulm
2022-03-07
Active, closed
D,L-MEthadone and mFOLFOX6 in Treatment of Advanced Colorectal Cancer
NCT05212012Chemo-refractory Colorectal Carcinoma
AIO-Studien-gGmbH
Phase 1/2
11
Hamburg, Mutlangen, Ulm
2022-02-17
Active, closed
Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15)
NCT05173987Endometrial Neoplasms
DrugsTaxotere·Paraplatin·Taxol·Docetaxel
Merck Sharp & Dohme LLC
Phase 3
280
Ulm, Bonn, Dresden, Berlin
2022-02-03
Active, closed
A Study of Anvumetostat in Participants With Advanced MTAP-null Solid Tumors (MTAPESTRY 101)
NCT05094336Advanced MTAP-null Solid Tumors
DrugsAnvumetostat·Docetaxel
Amgen
Phase 1/2
329
Halle, Heidelberg, Ulm, Würzburg
2022-02-01
Active, closed
A Study to Learn About the Effect of Higher Doses of Nusinersen (BIIB058) Given as Injections to Participants With Spinal Muscular Atrophy (SMA) Who Were Previously Treated With Risdiplam (ASCEND)
NCT05067790Spinal Muscular Atrophy
DrugNusinersen
Biogen
Phase 3
45
Heidelberg, Ulm, Munich, Essen
2022-01-21
Active, closed
Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD
NCT05407636AMD, nAMD, Wet Age-related Macular Degeneration, wAMD
DrugsEylea·Aflibercept
AbbVie
Phase 3
735
Freiburg im Breisgau, Ulm, Bonn, Münster, Ludwigshafen am Rhein, Hamburg, Püttlingen
2022-01-13
Recruiting
Immune Modulation by Exosomes in COVID-19
NCT05191381COVID-19, Critical Illness, Hypercytokinemia, Lung Fibrosis
University of Ulm
Observational
40
Ulm
2021-12-22
Active, closed
Venetoclax in Addition to Blinatumomab in Adult Patients With Relapsed/Refractory B Cell Precursor Acute Lymphoblastic Leukemia Relapsed/Refractory B Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL)
NCT05182385ALL, Recurrent, Adult
DrugsVenclyxto·Blinatumomab·Venetoclax
Goethe University
Phase 1/2
30
Tübingen, Ulm, Frankfurt am Main, Dresden, Berlin, Cologne, Düsseldorf, Erlangen
2021-12-15
Active, closed
Prognostic Role of Circulating Tumor DNA in Resectable Pancreatic Cancer
NCT04246203Pancreas Cancer
Ludwig-Maximilians - University of Munich
Observational
200
Munich, Berlin, Cologne, Hamburg, Ulm
2021-12-12
Active, closed
A Study to Assess Disease Activity in Adult Participants With Axial Spondyloarthritis Who Receive Upadacitinib in a Real-world Setting
NCT05094128Axial Spondylarthritis (r-axSpA)
DrugUpadacitinib
AbbVie
Observational
338
Baden-Baden, Heidelberg, Stuttgart, Tübingen, Ulm, Hoppegarten, Potsdam, Bruchhausen-Vilsen
2021-11-22
Active, closed
Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC
NCT05043090Papillary Renal Cell Carcinoma
DrugsSavolitinib·Sunitinib·Durvalumab
AstraZeneca
Phase 3
148
Hamburg, Hanover, München, Ulm
2021-10-28
Active, closed
A Study in Advanced or Metastatic Gastrointestinal Cancers Exploring Treatment Combinations With Pelareorep and Atezolizumab
NCT07280377Anal Cancer Metastatic, Squamous Cell Carcinoma of the Anus Stage Unspecified, Pancreatic Cancer Metastatic, Unresectable Pancreatic Carcinoma
DrugsGemcitabine and nab-paclitaxel·Pelareorep·Lonsurf·Trifluridine/Tipiracil
Oncolytics Biotech
Phase 1/2
122
Heidelberg, Heilbronn, Tübingen, Ulm, Augsburg, München, Hamburg, Frankfurt am Main
2021-10-27
Active, closed
A Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomide With a US Extension of Mosunetuzumab in Combination With Lenalidomide in Participants With Follicular Lymphoma
NCT04712097Relapsed or Refractory Follicular Lymphoma
DrugsMosunetuzumab·Lenalidomide·Rituximab
Hoffmann-La Roche
Phase 3
478
Berlin, Dresden, Halle, Heidelberg, Regensburg, Rostock, Ulm
2021-10-27
Recruiting
A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)
NCT04929223Metastatic Colorectal Cancer
DrugsDivarasib·Tiragolumab·Inavolisib·Folfiri
Hoffmann-La Roche
Phase 1
542
Berlin, Bochum, Dresden, Düsseldorf, Hamburg, Heilbronn, München, Ulm
2021-10-22
Active, closed
A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NET
NCT05050942Gastro-enteropancreatic Neuroendocrine Tumor
DrugsCAM2029·Octreotide LAR
Camurus AB
Phase 3
332
Berlin, Erlangen, Essen, Hamburg, Heidelberg, Mannheim, Ulm
2021-10-22
Recruiting
A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
NCT05020236Multiple Myeloma
DrugsDarzalex·Elranatamab·Pomalidomide·Daratumumab
Pfizer
Phase 3
893
Ulm, Würzburg, Berlin, Braunschweig, Chemnitz, München
2021-10-04
Recruiting
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
NCT05006716B-cell Malignancy, Marginal Zone Lymphoma, Follicular Lymphoma, Non-Hodgkin Lymphoma
DrugTacabrutideg
BeOne Medicines
Phase 1/2
645
Cologne, Dresden, Leipzig, Lübeck, Mainz, München, Ulm
2021-09-13
Active, closed
A Study to Investigate the Safety, Tolerability, and Processing by the Body of Intravenous and Subcutaneous RO7121932 Administration in Participants With Multiple Sclerosis
NCT05704361Multiple Sclerosis
Hoffmann-La Roche
Phase 1
119
Dresden, Göttingen, München, Münster, Tübingen, Ulm
2021-08-11
Active, closed
OSE2101 Alone or in Combination With Pembrolizumab vs BSC in Patient With Platinum-sensitive Recurrent OC
NCT04713514Platinum-sensitive Ovarian Cancer, Relapsed Ovarian Cancer
DrugsTedopi·Keytruda·Pembrolizumab
ARCAGY/ GINECO GROUP
Phase 2
180
Dresden, Essen, Leipzig, Mainz, Mannheim, Ulm
2021-08-05
Active, closed
Long-term Safety and Tolerability of Iptacopan in Patients With Paroxysmal Nocturnal Hemoglobinuria
NCT04747613Paroxysmal Nocturnal Hemoglobinuria
DrugIptacopan
Novartis Pharmaceuticals
Phase 3
208
Dresden, Aachen, Essen, Hamburg, Riesa, Ulm
2021-07-27
Recruiting
A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis
NCT04951622Myasthenia Gravis
DrugNipocalimab
Janssen Research & Development, LLC
Phase 3
199
Berlin, Göttingen, Leipzig, Lübeck, Ulm, Wiesbaden
2021-07-15
Recruiting
HighFLO Study - HighLife Trans-septal Mitral Valve Replacement (TSMVR) Feasibility Study of the Open Cell CLARITY Valve
NCT04888247Mitral Regurgitation
HighLife SAS
Not applicable
30
Munich, Ulm
2021-07-01
Active, closed
Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease
NCT04915755Neoplasms, Breast
DrugNiraparib
GlaxoSmithKline
Phase 3
40
Berlin, Cologne, Erlangen, Essen, Mannheim, München, Ulm
2021-06-28
Active, closed
FUSION: A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ION363 in Amyotrophic Lateral Sclerosis Participants With Fused in Sarcoma Mutations (FUS-ALS)
NCT04768972Amyotrophic Lateral Sclerosis
Ionis Pharmaceuticals, Inc.
Phase 3
89
Rostock, Ulm
2021-06-14
Recruiting
A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
NCT04895709Cervical Cancer, Gastric/Gastroesophageal Junction Adenocarcinoma, Microsatellite Stable Colorectal Cancer, Non-Small-Cell Lung Cancer
DrugsImzokitug·Pumitamig·Docetaxel·Nivolumab
Bristol-Myers Squibb
Phase 1/2
1,109
Ulm, Dresden, Essen, Frankfurt, Würzburg
2021-05-27
Recruiting
A Study of BGB-11417 in Participants With Myeloid Malignancies
NCT04771130Acute Myeloid Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasm
DrugsPosaconazole·Sonrotoclax·Azacitidine
BeOne Medicines
Phase 1/2
260
Leipzig, Ulm
2021-05-24
Active, closed
A Study of BIIB067 (Tofersen) Initiated in Clinically Presymptomatic Adults With a Confirmed Superoxide Dismutase 1 Mutation
NCT04856982Amyotrophic Lateral Sclerosis Associated With a SOD1 Gene Mutation
DrugTofersen
Biogen
Phase 3
158
Ulm, Hanover
2021-05-17
Active, closed
A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Participants With High-risk Muscle-invasive Bladder Cancer (MIBC) Who Are ctDNA Positive Following Cystectomy
NCT04660344Muscle-invasive Bladder Cancer
DrugsTecentriq·Atezolizumab
Hoffmann-La Roche
Phase 3
761
Düsseldorf, Halle, Herne, Tübingen, Ulm, Würzburg
2021-05-03
Recruiting
Immunoadsorption Versus Plasma Exchange for Treatment of Guillain-Barré Syndrome (GBS)
NCT04871035GBS
University of Ulm
Observational
20
Ulm
2021-04-28
Active, closed
A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab
NCT04770896Unresectable Hepatocellular Carcinoma
DrugsSorafenib·Tecentriq·Atezolizumab·Lenvatinib
Hoffmann-La Roche
Phase 3
557
Frankfurt, Hanover, Mainz, Tübingen, Ulm
2021-04-26
Recruiting
Vitrectomy, Subretinal Tissue Plasminogen Activator (TPA) and Intravitreal Gas for Submacular Haemorrhage Secondary to Exudative (Wet) Age-related Macular Degeneration (TIGER).
NCT04663750Eye Diseases, Macular Degeneration, Wet, Sub-Macular Hemorrhage
King's College Hospital NHS Trust
Phase 3
210
Bonn, Hamburg, Ludwigshafen, München, Münster, Sulzbach, Ulm, Würzburg
2021-04-16
Active, closed
Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2)
NCT04603495Myelofibrosis, Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
DrugsPelabresib·Ruxolitinib
Novartis Pharmaceuticals
Phase 3
430
Ulm, Augsburg, Halle, Jena, Hamburg
2021-04-09
Active, closed
Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)
NCT04662255Lymphoma, Mantle-Cell
DrugsPirtobrutinib·Ibrutinib·Acalabrutinib·Zanubrutinib
Loxo Oncology, Inc.
Phase 3
500
Ulm, Würzburg, Giessen, Münster, Koblenz, Mainz, Lübeck, Hamburg
2021-04-08
Recruiting
Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
NCT04728893Hematologic Malignancies, Waldenstroms Macroglobulinaemia, Non-Hodgkins Lymphoma, Chronic Lymphocytic Leukaemia
DrugNemtabrutinib
Merck Sharp & Dohme LLC
Phase 2
490
Ulm, Cologne, Siegen, Dresden
2021-04-05
Active, closed
A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS)
NCT04586010Relapsing Multiple Sclerosis
DrugsFenebrutinib·Teriflunomide
Hoffmann-La Roche
Phase 3
746
Berlin, Böblingen, Dresden, Giessen, Kiel, Stuttgart, Tübingen, Ulm
2021-03-17
Active, closed
Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
NCT04666038Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
DrugsIdelalisib·Truxima·Pirtobrutinib·Bendamustine
Loxo Oncology, Inc.
Phase 3
238
Heidelberg, Ulm, Kerpener, Langenbeckstraße 1, Koelner Platz 1, Kiel, Lübeck, Berlin
2021-03-09
Recruiting
Efficacy and Safety of Masitinib Versus Placebo in the Treatment of ALS Patients
NCT03127267Amyotrophic Lateral Sclerosis
DrugsMasitinib·Riluzole
AB Science
Phase 3
495
Ulm
2021-02-02
Recruiting
Neuroimmunology Registry and Biobank
NCT06958341Encephalopathy, Psychosis, Impaired Consciousness, Epilepsy
Charite University, Berlin, Germany
Observational
300
Berlin, Ulm
2021-02-01
Active, closed
Transcatheter Repair of Tricuspid Regurgitation With Edwards PASCAL Transcatheter Valve Repair System
NCT04614402Tricuspid Valve Insufficiency
Edwards Lifesciences
Observational
300
Tübingen, Ulm, München, Cologne, Essen, Bad Oeynhausen, Bonn, Leipzig
2021-01-15
Active, closed
A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL
NCT04521231B Cell Precursor Acute Lymphoblastic Leukemia
DrugBlinatumomab
Amgen
Phase 1/2
181
Augsburg, Berlin, Cologne, Jena, Leipzig, Tübingen, Ulm
2021-01-04
Active, closed
A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)
NCT04548999Multiple Sclerosis
DrugsOcrelizumab·Methylprednisolone
Hoffmann-La Roche
Phase 3
769
Dresden, Greifswald, Hanover, Leipzig, Münster, Tübingen, Ulm, Wiesbaden
2020-12-03
Active, closed
A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)
NCT04544436Multiple Sclerosis
DrugsOcrelizumab·Methylprednisolone
Hoffmann-La Roche
Phase 3
864
Berlin, Bochum, Dresden, Kiel, Leipzig, Ulm, Wiesbaden
2020-11-26
Active, closed
Sacituzumab Govitecan in Primary HER2-negative Breast Cancer
NCT04595565HER2-negative Breast Cancer, Triple Negative Breast Cancer
DrugsXeloda·Paraplatin·Sacituzumab Govitecan·Capecitabine
GBG Forschungs GmbH
Phase 3
1,332
Böblingen, Esslingen am Neckar, Freiburg im Breisgau, Karlsruhe, Mannheim, Nürtingen, Reutlingen, Ulm
2020-10-28
Active, closed
A Study Evaluating the Efficacy and Safety of Crovalimab Versus Eculizumab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Not Previously Treated With Complement Inhibitors
NCT04434092Paroxysmal Nocturnal Hemoglobinuria
DrugsCrovalimab·Eculizumab
Hoffmann-La Roche
Phase 3
210
Essen, Ulm
2020-10-08
Active, closed
Assessment of Efficacy and Safety of Monalizumab Plus Cetuximab Compared to Placebo Plus Cetuximab in Recurrent or Metastatic Head and Neck Cancer
NCT04590963Squamous Cell Carcinoma of the Head and Neck
DrugsMonalizumab·Cetuximab
AstraZeneca
Phase 3
370
Berlin, Essen, Freiburg im Breisgau, Hanover, Leipzig, Ulm, Würzburg
2020-10-02
Recruiting
Multidimensional Assessment of Infant, Parent and Staff Outcomes During a Family Centered Care Enhancement Project
NCT05286983Family Centered Care
University of Giessen
Observational
495
Ulm, Giessen
2020-10-01
Active, closed
Study Comparing Intravenous (IV)/Subcutaneous (SC) Risankizumab to IV/SC Ustekinumab to Assess Change in Crohn's Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn's Disease (CD)
NCT04524611Crohn's Disease (CD)
DrugsSkyrizi·Risankizumab·Ustekinumab
AbbVie
Phase 3
527
Freiburg im Breisgau, Mannheim, Ulm, Erlangen, Regensburg, Frankfurt am Main, Hanover, Lüneburg
2020-09-30
Recruiting
BRAF Inhibitor Encorafenib And Cetuximab Real Life Investigation of Next Generation CRC Treatment
NCT04673955Metastatic Colorectal Carcinoma
DrugsEncorafenib·Erbitux·Cetuximab
Pierre Fabre Pharma GmbH
Observational
500
Offenburg, Ulm, Augsburg, Donauwörth, Erlangen, München, Würzburg, Aschaffenburg
2020-09-03
Active, closed
Adjuvant Therapy With Abemaciclib + SOC ET vs. SOC ET in Clinical or Genomic High Risk, HR+/HER2- EBC
NCT04565054Breast Cancer Female
DrugAbemaciclib
Women's Cancer Study Group GmbH
Phase 3
1,260
Freiburg im Breisgau, Heilbronn, Ravensburg, Ulm, Weinheim, Baden-Baden, Tübingen, Augsburg
2020-09-02
Recruiting
BOLD-100 in Combination With FOLFOX for the Treatment of Advanced Solid Tumours
NCT04421820Colorectal Cancer, Pancreatic Cancer, Gastric Cancers, Cholangiocarcinoma
DrugsBOLD-100·Oxaliplatin
Bold Therapeutics, Inc.
Phase 1/2
220
Bonn, Ulm
2020-08-28
Active, closed
MitraClip REPAIR MR Study
NCT04198870Mitral Valve Regurgitation
Abbott Medical Devices
Not applicable
500
Ulm, Frankfurt am Main, Bad Oeynhausen, Mainz, München, Rostock
2020-07-21
Active, closed
A Study to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL)
NCT04245839Lymphoma, Non-Hodgkin
DrugsBreyanzi·Fludarabine·Cyclophosphamide
Celgene
Phase 2
276
Ulm, Regensburg, Cologne, Karlsruhe, Munich
2020-07-14
Active, closed
A Study Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Participants With PIK3CA-Mutant, Hormone Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer
NCT04191499Breast Cancer
DrugsInavolisib·Palbociclib·Fulvestrant
Hoffmann-La Roche
Phase 2/3
325
Berlin, Essen, Heidelberg, Mannheim, Trier, Ulm
2020-01-29
Recruiting
Study of Safety & PK of Luspatercept (ACE-536) in Pediatric Participants With Beta (β)-Thalassemia
NCT04143724Beta-Thalassemia
DrugLuspatercept
Celgene
Phase 2
99
Essen, Ulm
2019-11-07
Active, closed
IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia
NCT04086264Acute Myeloid Leukemia
DrugsIMGN632·Venclyxto·Decitabine·Venclexta
AbbVie
Phase 1/2
218
Ulm, Münster, Leipzig
2019-11-06
Recruiting
A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
NCT04065399Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Mixed Lineage Acute Leukemia, Mixed Phenotype Acute Leukemia
DrugsCobicistat·Revumenib
Syndax Pharmaceuticals
Phase 1/2
447
Ulm, Essen, Greifswald, Gutenberg, Hamburg, Leipzig, Nuremberg
2019-11-05
Active, closed
Rollover Study for Continued Safety and Tolerability in Subjects Treated With Spartalizumab Alone or in Combination With Other Study Treatments
NCT04058756Advanced Solid Tumors
DrugSpartalizumab
Novartis Pharmaceuticals
Phase 1
120
Jena, Essen, Heidelberg, Ulm
2019-10-30
Recruiting
Burden, Mortality and Supply Costs in Intensive Care Unit Patients
NCT04094428Burden, Dependency, Mortality, End-of-life Care, Intensive Care Unit
University of Ulm
Observational
700
Ulm
2019-10-21
Active, closed
A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis
NCT04033445Ulcerative Colitis
DrugGuselkumab
Janssen Research & Development, LLC
Phase 2/3
1,064
Berlin, Halle, Hanover, Jerichow, Lüneburg, Saarbrücken, Ulm
2019-09-26
Active, closed
MiCLASP Post Market Clinical Follow-Up (PMCF) Study
NCT04430075Mitral Regurgitation, Mitral Insufficiency
Edwards Lifesciences
Observational
1,000
Bad Krozingen, Tübingen, Ulm, Erlangen, München, Bernau bei Berlin, Giessen, Göttingen
2019-08-23
Active, closed
A Study to Investigate the Efficacy of Zanubrutinib Plus Rituximab Compared With Bendamustine Plus Rituximab in Adults With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation
NCT04002297Mantle Cell Lymphoma; Non-Hodgkin Lymphoma
DrugsBendamustine·Zanubrutinib·Rituximab
BeOne Medicines
Phase 3
510
Cologne, Heidelberg, Munich, Ulm, Wuppertal
2019-08-20
Active, closed
Reduced Intensity Radio-chemotherapy for Stage IIA/B Seminoma
NCT03937843Seminoma, Testicular Cancer
DrugsEtoposide·Cisplatin·Carboplatin
Swiss Cancer Institute
Phase 2
135
München, Berlin, Essen, Hamburg, Ludwigsburg, Tübingen, Ulm
2019-07-29
Active, closed
Transcatheter Repair of Tricuspid Regurgitation With Edwards Cardioband TR System Post Market Study (TriBAND)
NCT03779490Tricuspid Regurgitation, Tricuspid Insufficiency
Edwards Lifesciences
Observational
150
Ulm, Bad Oeynhausen, Cologne, Berlin, Bonn, Dresden, Erlangen, Göttingen
2019-07-24
Active, closed
Adj. Marker-adjusted Personalized Therapy Comparing ET+Ribociclib vs Chemotherapy in Intermediate Risk, HR+/HER2- EBC
NCT04055493Breast Cancer Female
DrugRibociclib
Women's Cancer Study Group GmbH
Phase 3
1,684
Aalen, Baden-Baden, Böblingen, Freiburg im Breisgau, Heilbronn, Ludwigsburg, Tübingen, Ulm
2019-07-02
By invitation
Influence of Adherence to Growth Hormone Therapy (GHT) With Norditropin® on Near Final Height in Patients With Growth Hormone Deficiency (GHD) and Born Small for Gestational Age (SGA)
NCT03972345Growth Hormone Deficiency in Children, Born Small for Gestational Age
Novo Nordisk A/S
Observational
750
Ulm
2019-06-21
Active, closed
A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study
NCT03768063Cancer
DrugsEmactuzumab·Rucaparib·Cobimetinib·Vemurafenib
Hoffmann-La Roche
Phase 3
1,000
Ulm, Regensburg, Lübeck, Essen, Freiburg im Breisgau, Gauting, Gera, Immenhausen
2019-02-28
Active, closed
Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689)
NCT03765918Head and Neck Neoplasms
DrugsKeytruda·Cisplatin·Pembrolizumab
Merck Sharp & Dohme LLC
Phase 3
714
Tübingen, Ulm, Erlangen, Munich, München, Frankfurt am Main, Kassel, Cologne
2018-12-17
Recruiting
PACAREG: a Multicenter Registry Trial in Pancreatic Ductal Adencarcinoma
NCT04099134Pancreas Adenocarcinoma, Pancreas Cancer
University of Ulm
Observational
5,000
Ulm
2018-10-10
Active, closed
Elotuzumab in Combination With Carfilzomib, Lenalidomide and Dexamethasone (E-KRd) Versus KRd in MM
NCT03948035Newly Diagnosed Multiple Myeloma
DrugsElotuzumab·Carfilzomib·Lenalidomide·Dexamethasone
Wuerzburg University Hospital
Phase 3
576
Freiburg im Breisgau, Mutlangen, Ravensburg, Stuttgart, Ulm, Villingen-Schwenningen, Amberg, Augsburg
2018-08-28
Active, closed
A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis
NCT03398135Ulcerative Colitis (UC)
DrugsSkyrizi·Risankizumab
AbbVie
Phase 3
1,242
Freiburg im Breisgau, Heidelberg, Mannheim, Ulm, Erlangen, Munich, Frankfurt am Main, Kassel
2018-08-28
Active, closed
A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple Sclerosis
NCT03523858Progressive Multiple Sclerosis (PMS)
DrugOcrelizumab
Hoffmann-La Roche
Phase 3
927
Dresden, Greifswald, Stuttgart, Ulm, Westerstede, Wiesbaden
2018-05-28
Active, closed
A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn's Disease
NCT03105102Crohn's Disease
DrugsSkyrizi·Risankizumab
AbbVie
Phase 3
1,336
Freiburg im Breisgau, Heidelberg, Mannheim, Ulm, Dachau, Erlangen, Regensburg, Frankfurt am Main
2018-04-09
Active, closed
Development of Novel Clinical Endpoints in Intermediate AMD
NCT03349801Age Related Macular Degeneration (AMD)
Frank G. Holz
Observational
718
Bonn, Cologne, Freiburg im Breisgau, Munich, Münster, Tübingen, Ulm
2018-03-26
Active, closed
A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433
NCT03345823Crohn's Disease
DrugUpadacitinib
AbbVie
Phase 3
747
Mannheim, Ulm, Erlangen, Frankfurt am Main, Saarbrücken, Kiel, Berlin, Essen
2018-03-21
Recruiting
Registry for Patients With Lipodystrophy
NCT03553420Lipodystrophy Acquired, Lipodystrophy Congenital
University of Ulm
Observational
5,000
Hanover, Leipzig, Münster, Ulm
2017-12-16
Active, closed
Study Assessing The "Best of" Radiotherapy vs the "Best of" Surgery in Patients With Oropharyngeal Carcinoma
NCT02984410Oropharyngeal Cancer, Supraglottic Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma
European Organisation for Research and Treatment of Cancer - EORTC
Not applicable
112
Cologne, Halle, Hamburg, Jena, Leipzig, München, Tübingen, Ulm
2017-11-27
Recruiting
Systematic Assessment of Laryngopharyngeal Function in Patients With Neurodegenerative Diseases
NCT04706234Multiple System Atrophy, Parkinson Disease, Progressive Supranuclear Palsy, Motor Neuron Disease
Kliniken Beelitz GmbH
Observational
350
Ulm, Beelitz-Heilstätten, Hanover, Münster, Dresden, Stadtroda, Hamburg
2017-09-01
Active, closed
Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer
NCT03155997Breast Cancer
DrugAbemaciclib
Eli Lilly and Company
Phase 3
5,637
Freiburg im Breisgau, Friedrichshafen, Ludwigsburg, Tübingen, Ulm, Amberg, Augsburg, Erlangen
2017-07-12
Active, closed
A Study to Evaluate the Efficacy of Prasinezumab (RO7046015/PRX002) in Participants With Early Parkinson's Disease
NCT03100149Parkinson's Disease
DrugPrasinezumab
Hoffmann-La Roche
Phase 2
316
Berlin, Düsseldorf, Kassel, Leipzig, Marburg, München, Tübingen, Ulm
2017-06-27
Active, closed
Study of AG-120 (Ivosidenib) vs. Placebo in Combination With Azacitidine in Participants With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation
NCT03173248Newly Diagnosed Acute Myeloid Leukemia (AML), Untreated AML, AML Arising From Myelodysplastic Syndrome (MDS), Leukemia, Myeloid, Acute
DrugsIvosidenib·Azacitidine
Institut de Recherches Internationales Servier
Phase 3
146
Essen, Chemnitz, Berlin, Hanover, Leipzig, München, Ulm
2017-06-26
Active, closed
A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL
NCT02972840Lymphoma, Mantle Cell
DrugsAcalabrutinib·Bendamustine·Rituximab
Acerta Pharma BV
Phase 3
635
Heidelberg, München, Münster, Nordrhein-Westfalen, Ravensburg, Rheinland-Pfalz, Ulm
2017-04-05
Active, closed
A Study of Venetoclax in Combination With Azacitidine Versus Azacitidine in Treatment Naïve Participants With Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Therapy
NCT02993523Acute Myeloid Leukemia (AML)
DrugsAzacitidine·Venetoclax
AbbVie
Phase 3
443
Ulm, Frankfurt am Main, Münster, Halle, Hamburg, Hanover
2017-02-02
Active, closed
A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL
NCT02970318Chronic Lymphocytic Leukemia
DrugsIdelalisib·Acalabrutinib·Bendamustine·Rituximab
Acerta Pharma BV
Phase 3
310
Aschaffenburg, Dresden, Mutlangen, München, Ulm
2017-02-02
Recruiting
HDClarity: a Multi-site Cerebrospinal Fluid Collection Initiative to Facilitate Therapeutic Development for Huntington's Disease
NCT02855476Huntington's Disease
University College, London
Observational
2,500
Ulm, Dresden, Bochum, Erlangen, Münster, Taufkirchen
2017-01-01
Recruiting
MEASuRE: Metreleptin Effectiveness And Safety Registry
NCT02325674Generalised Lipodystrophy, Partial Lipodystrophy
DrugMetreleptin
Chiesi Farmaceutici S.p.A.
Observational
100
Ulm, Hanover, Münster, Leipzig
2016-10-11
Active, closed
A Study of Abemaciclib (LY2835219) Plus Tamoxifen or Abemaciclib Alone in Women With Metastatic Breast Cancer
NCT02747004Metastatic Breast Cancer
DrugsTamoxifen·Abemaciclib
Eli Lilly and Company
Phase 2
234
Ulm, Hamburg
2016-09-14
Active, closed
A Study to Assess the Safety and Efficacy of Two Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) Harboring IDH Mutations Who Are Not Candidates to Receive Intensive Induction Chemotherapy
NCT02677922Leukemia, Myeloid, Acute
DrugsEnasidenib·Ivosidenib·Azacitidine
Celgene
Phase 1/2
130
Berlin, Dresden, Ulm
2016-06-03
Active, closed
A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer
NCT02711553Biliary Tract Cancer, Metastatic Cancer, Advanced Cancer
DrugsRamucirumab·Gemcitabine·Cisplatin
Eli Lilly and Company
Phase 2
309
Tübingen, Ulm, Erlangen, Hanover, Berlin, Hamburg
2016-05-19
Active, closed
A Long Term Safety Study of ND0612 Administered as a Continuous SC Infusion in Advanced Parkinson's Disease
NCT02726386Parkinson's Disease
NeuroDerm Ltd.
Phase 2
214
Beelitz-Heilstätten, Bochum, Bremerhaven, Dresden, Haag in Oberbayern, Ulm
2016-05-04
Recruiting
The Oxford Risk Factors And Non-Invasive Imaging Study
NCT05169333Cardiovascular Diseases, Cardiovascular Risk Factors
University of Oxford
Observational
250,000
Erlangen, Ulm
2016-02-23
Active, closed
Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation
NCT02632708Newly Diagnosed Acute Myeloid Leukemia (AML), Untreated AML, AML Arising From Myelodysplastic Syndrome (MDS), AML Arising From Antecedent Hematologic Disorder (AHD)
DrugsEnasidenib·Idarubicin·Mitoxantrone·Ivosidenib
Institut de Recherches Internationales Servier
Phase 1
153
Ulm
2015-12-31
Recruiting
Registry Study on Epidemiological and Biological Disease Profile as Well as Clinical Outcome in Patients With Low Grade Gliomas
NCT02686229Glioma
University of Ulm
Observational
300
Ulm
2015-11-15
Active, closed
Riociguat in Children With Pulmonary Arterial Hypertension (PAH)
NCT02562235Hypertension, Pulmonary
DrugRiociguat
Bayer
Phase 3
24
Heidelberg, Ulm, Berlin
2015-10-29
Active, closed
The Ruxo-BEAT Trial in Patients With High-risk Polycythemia Vera or High-risk Essential Thrombocythemia
NCT02577926Polycythemia Vera (PV), Essential Thrombocythemia (ET)
DrugsJakavi·Ruxolitinib
RWTH Aachen University
Phase 2
207
Mannheim, Ulm, Winnenden, Aschaffenburg, Müchen, Nuremberg, Hamburg, Mainz
2015-10
Active, closed
Post-operative Adjuvant Treatment for HPV-positive Tumours (PATHOS)
NCT02215265Human Papillomavirus (HPV)-Positive Oropharyngeal Cancer
DrugCisplatin
Lisette Nixon
Phase 3
1,269
Berlin, Giessen, Hamburg, Homburg, Leipzig, Potsdam, Solingen, Ulm
2015-10
Active, closed
Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Participants With High Risk Chronic Lymphocytic Leukemia (CLL)
NCT02477696Chronic Lymphocytic Leukemia
DrugsIbrutinib·Acalabrutinib
Acerta Pharma BV
Phase 3
533
München, Ulm
2015-07-28
Active, closed
CINC424A2X01B Rollover Protocol
NCT02386800Primary Myelofibrosis, Polycythemia Vera, Graft Versus Host Disease, Acute Myeloid Leukemia
DrugsJakavi·Ruxolitinib
Novartis Pharmaceuticals
Phase 4
279
Dresden, Jena, Aachen, Hamburg, Magdeburg, Mainz, Ulm
2015-03-05
Active, closed
A Study of Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast Cancer
NCT02246621Breast Cancer
DrugsAnastrozole·Abemaciclib·Letrozole
Eli Lilly and Company
Phase 3
493
Ludwigsburg, Ulm, München, Wiesbaden, Düsseldorf, Lübeck, Hamburg
2014-11-06
Active, closed
A Non-Interventional Clinical Study to Evaluate Long-Term Safety and Effectiveness of HUMIRA (Adalimumab) in Pediatric Patients With Moderately to Severely Active Crohn's Disease (CD)
NCT02130362Crohn's Disease
AbbVie
Observational
1,446
Ulm, Erlangen, Munster, Osnabrück, Aachen, Dresden, Forchheim, Freiburg im Breisgau
2014-08-28
Recruiting
Monocyte Profiles in Critically Ill Patients With Pseudomonas Aeruginosa Sepsis
NCT03044223Pseudomonas Infections, Pseudomonas Septicemia, Pseudomonas; Pneumonia, Pseudomonal Bacteraemia
University of Ulm
Observational
100
Ulm
2014-08
Active, closed
Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 Weeks
NCT02051218Metastatic Breast Cancer, Metastatic Prostate Cancer, Bone Metastases
DrugsReduced·Xgeva·Denosumab
Swiss Cancer Institute
Phase 3
1,380
Düsseldorf, Göttingen, Lübeck, Ulm
2014-07-16
Recruiting
Praegnant Breast Cancer: Early/Advanced/Metastatic
NCT02338167Advanced/Metastatic Breast Cancer, Breast Cancer (Early Breast Cancer)
University Hospital Tuebingen
Observational
13,500
Böblingen, Freiburg im Breisgau, Heidelberg, Karlsruhe, Mannheim, Nürtingen, Tübingen, Ulm
2014-06
Active, closed
Weight Loss Surgery in Adolescents With Extreme Obesity
NCT02062164Obesity, Extreme Obesity
Prof. Dr. Martin Wabitsch
Observational
66
Berlin, Datteln, Essen, Leipzig, Ulm
2013-11
Recruiting
Hemophagocytosis in Critically Ill Adult Patients
NCT01913938Hemophagocytosis
University of Ulm
Observational
40
Ulm
2013-07
Active, closed
A Long-Term Registry of Humira® (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC)
NCT01848561Ulcerative Colitis (UC)
AbbVie
Observational
8,250
Freiburg im Breisgau, Heidelberg, Mannheim, Sigmaringen, Ulm, Erlangen, Memmingen, Munich
2013-04-29
Rows per page Showing 1–348 of 348
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a German investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 1 October 2026. https://priyalifescience.com/clinical-trials-germany/city/ulm

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Germany and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 5,051 studies in total at the last sync on 26 Sep 2026, 19:51 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 348 of those studies with a site in Ulm.

How many clinical trials are recruiting in Ulm?

179 of the 348 studies on this page are recruiting new participants as of the 26 Sep 2026, 19:51 UTC sync. A further 10 have not yet opened recruitment, 152 are active but closed to new participants, and 7 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Ulm), 348 studies
PhaseStudiesRecruitingShare
Phase 31194734.2%
Phase 2672819.3%
Observational624617.8%
Phase 1/2362210.3%
Not applicable31208.9%
Phase 12095.7%
Phase 2/3742%
Phase 4631.7%

Most active sponsors

Lead sponsors with the most studies (Ulm)
Lead sponsorStudiesRecruiting
University of Ulm2420
Hoffmann-La Roche236
AbbVie215
Novartis Pharmaceuticals144
Eli Lilly and Company138
Sanofi118
Merck Sharp & Dohme LLC106
Bristol-Myers Squibb95
Pfizer88
BeOne Medicines64
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.